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Summary  
Autophagy is an evolutionary conserved degradative pathway, where damaged or surplus 
cytosolic components are sequestered into double membrane vesicles, autophagosomes, which 
become degraded through the lysosomal system. The autophagy is a dynamic process, which is 
depended of transport of autophagosomes along microtubule, to become degraded by 
lysosomes. One of the proteins involved in this transport process is FYVE and Coiled-coil [CC] 
domain containing protein 1 (FYCO1). FYCO1 is involved in transporting autophagosomes 
and late endosomes along microtubules, in the plus-end direction, by interacting with kinesin. 
FYCO1 interacts with membranes through phosphatidylinositol-3 phosphate via its FYVE 
domain. It is regulated by RAB7 interaction, via its coiled-coil region, and involved in 
autophagy through its interaction with LC3, via its LIR-region. No interaction partners or roles 
for the N-terminal RUN domain or the C-terminal GOLD domain have been revealed. 
Interestingly, patients with autosomal-recessive congenital cataracts have been identified with 
a mutation, L1376P, in the GOLD domain of FYCO1. This mutation has been suggested to link 
FYCO1 and human lens development and transparency together. The major aim for this study 
was to identify putative interaction candidates for the GOLD domain and examine the effect 
L1376P mutation had on the GOLD domain. From our mass spectrometry study, the GOLD 
domain may seem to be involved in protein-protein interactions. 182 proteins co-precipitated 
together with the insolated GOLD domain, but it is unknown if these interact with the GOLD 
domain directly or indirectly. Of these proteins, TUBA4A, DNAJA1, TXNDC5, NIPSNAP1, 
NIPSNAP2 (GBAS), ARF4, VPS4A, RUVBL2 and MON1B were selected for further 
examination. The GOLD domain showed different distribution when co-expressed with 
TUBA4A and VPS4A. TUBA4A was showed to be located at the centrosome in association 
with the GOLD domain. TUBA4A redistribute the GOLD domain to centrosomes. In addition, 
VPS4A was observed to localize as aggregates, and it was shown in this study that the GOLD 
domain may be redistributed to these VPS4A structures. It is still unclear if these interactions 
with the GOLD domain are indirect or direct. In addition, we studied the L1376P mutation of 
the GOLD domain. This mutation dramatically changes the subcellular distribution of an over-
expressed GFP-GOLD domain construct from diffuse to many small aggregate-like structures. 
If this mutation has a similar effect on the full-length FYCO1 this may perhaps affect the 






aa    amino acid(s) 
Ab    Antibody 
APS     Ammonium peroxodisulfat 
Atg    autophagy- related genes 
CMA    Chaperone- mediated- autophagy 
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FM    Full growth Medium 
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1 Introduction  
1.1 The cytoskeleton 
Eukaryotic cells are composed of a dynamic network of protein filaments known as the 
cytoskeleton. The cytoskeleton is important for cellular shape, motility and spatial organization 
of cytosolic components. It is divided into three major classes: actin filaments, microtubules 
(MT) and intermediate filaments (Fletcher and Mullins, 2010, Bershadsky and Vasiliev, 2012). 
Actin filaments are helical polymers of actin protein. They are highly concentrated beneath the 
plasma membrane, and are important for cellular shape and movement (Blanchoin et al., 2014). 
MT are long, hollow cylinders made of tubulin protein (α-tubulin and β-tubulin), which 
assembles into linear protofilaments. MT are highly dynamic structures due to their ability to 
quickly become polymerized and depolymerized. MT are polar structures that have plus and 
minus ends with differing polymerization and depolymerization rates. They are crucial for 
neural polarity (Conde and Caceres, 2009) as well as for intracellular transport of organelles 
(Vale et al., 1985). The transport along MT requires motor proteins and two set of motor 
proteins: kinesins and dyneins. Actin filaments and MT can both bind and hydrolyze nucleoside 
triphosphates and generate a force by assemble head-to tail polarization, which contribute to 
the movements (Conde and Caceres, 2009, Mourino-Perez et al., 2016). The intermediate 
filaments are ropelike fibers, made of intermediate filament proteins. Intermediate filaments 
are linked to adhesive structures, such as desmosomes (connects cells together) and provide 
mechanical strength (Herrmann and Aebi, 2004) 
1.2 Vesicle and organelle movement by motor proteins on MT 
Intracellular vesicles and organelles are transported along MT by the motor proteins kinesins 
and dyneins (Hirokawa, 1998). Movement along MT is dependent on a cycle of association and 
dissociation of ATP. Most kinesins transport vesicles and organelles along MT in a plus-end 
manner (anterograde transport), and move along MT at a steady and slow rate. Kinesin-1 is a 
plus-end heterotetramer with two heavy chains and two light chains, whit each heavy chain 
containing an N-terminal nucleotide-binding motor domain (Cardoso et al., 2009). Two light 
chain dyneins are minus-end directed MT motor proteins and interact with dynactin to start the 
transportation. Dyneins are the largest and the fastest among the known molecular motor 
proteins and move through association and dissociation of ATP (Allan, 2011). Motor proteins 
are involved in vesicular transport, which is important for cellular homeostasis.  
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1.3 Rab GTPase family  
Rab proteins are master regulators in the endocytic pathway, regulating transport between 
organelles of endocytic- and secretory pathways with high specificity. The small monomeric G 
proteins (guanine nucleotide binding proteins) are Ras like GTPases, that mediate endosome 
targeting, by regulating docking and tethering. Through the Rab proteins intrinsic GTPase 
activity, they function as molecular switches by hydrolyzing guanosine-5` triphosphate (GTP) 
to guanosine-5 diphosphate (GDP (Stenmark, 2009). Rab proteins are important for linking 
membranous compartments to molecular motor proteins allowing for long distance transport of 
organelles along microtubule or actin tracks (Hammer Iii and Wu, 2002). A link has been 
discovered between different Rab proteins and autophagosomes in the regulation of autophagy 
(Ao et al., 2014).  
1.3.1 Regulation of autophagosome maturation by Rab GTPases 
The fusion- and transporting mechanisms of autophagosomes are regulated by Rab GTPases 
(Ao et al., 2014). One of the Rabs involved in autophagy is Rab7. It has been shown to regulate 
autophagosome formation (Lin et al., 2012) and maturation (Hyttinen et al., 2013). Rab7 is 
present on both late endosomes and autophagosomes. Rab7 is important for the fusion process 
via its binding to the homotypic fusion and protein sorting (HOPS) tethering complex. HOPS 
promotes tethering of membranes such as endosomes, vacuoles, autophagosome and lysosomes 
(Wang et al., 2011).  
 
Rab7 regulates MT transport direction through recrutment of effectors such as FYVE and 
coiled-coil domain containing 1 (FYCO1) (Pankiv et al., 2010) and oxysterol-binding protein 
related protein 1L (ORP1L)/ Rab-interacting lysosomal protein (RILP) (Cantalupo et al., 2001, 
van der Kant et al., 2013). The vesicles transported along MT in a plus- end-direction are bound 
to kinesin through FYCO1s coiled-coil (CC) region, and are regulated through the FYCO1 
interaction with Rab7 (Pankiv et al., 2010, Raiborg et al., 2015). In contrast, vesicles transported 
along MTs in a minus-end direction, are controlled and regulated by the production of the single 
multiprotein complex composed of dynein and HOPS complex. Through a combination of 
regulation and recruitment of HOPS complex and dynein motor proteins, MT minus- end 
transport and fusion can be regulated by the multiprotein complex, Rab7-RILP-ORP1L (van 
der Kant et al., 2013).  
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1.4 Cellular degradative systems 
Cellular homeostasis is obtained by degradation systems regulating the quality and the quantity 
of cytosolic components, such as organelles and proteins. Eukaryotic cells have two main 
intracellular degradation systems: the proteasome and the lysosomal pathway (Pickart and 
Cohen, 2004, Saftig and Klumperman, 2009). Proteasomal degradation serves as a protein 
quality control. Short-lived and misfolded proteins are ubiquitinated and transported into the 
proteasomes, by chaperones, where they are degraded (Adams, 2003). Protein aggregates are 
degraded by the lysosomal degradation pathway. Lysosomes are the terminal part of the 
endocytic pathway, and contain high levels of acidic content in addition to hydrolytic enzymes.  
Damaged or surplus proteins and organelles from the intracellular space are targeted for 
lysosomal degradation, as well as macromolecules obtained from the extracellular space (Saftig 
and Klumperman, 2009). Autophagy is the main intracellular degradation system and targets 
proteins and organelles for lysosomal degradation (Mizushima and Komatsu, 2011). There are 
three major classes of autophagy: macroautophagy, microautophagy and chaperone-mediated-
autophagy (CMA) (Figure 1.1). Macroautophagy is the major and most studies category of 
autophagy. Macroautophagy degrades proteins and organelles through the fusion of the double 
membrane autophagosome with the lysosome (Mizushima and Komatsu, 2011). In 
microautophagy, cytoplasmic components are engulfed by the lysosome through invagination 
of the lysosomal membrane (Li et al., 2011). In chaperone-mediated autophagy, substrates are 
directly translocated into lysosomes by the chaperone protein Hsc70 (heat shock cognate 70) 






 Figure 1.1: Autophagy classification. Autophagy is divided into three major classes: macroautophagy, 
microautophagy and chaperone-mediated-autophagy (CMA). Macroautophagy creates a double membrane 
structure (autophagosome) around the substrate, which is marked for degradation, by an autophagy receptor (i.e 
p62, NBR1). Degradation initiates once an autophagosome fuses with a lysosome. In microautophagy, the 
lysosome itself engulfs substrates, where it becomes degraded. Chaperone-mediated- autophagy (CMA) degrades 
ubiquitin-marked substrates, which becomes delivered into the lysosome with the help from chaperone-protein 
Hsc70 (Heat shock protein 70) and lysosomal transmembrane protein (Lamp-2A). All three autophagy classes 
produce degradation products such as, amino acids, which is used in anabolic processes. Figure adopted from 





1.4.1 Macroautophagy (hereafter autophagy) 
Autophagy is an evolutionary conserved degradation pathway, where damaged or surplus 
cytosolic components are degraded through the lysosomal system. The degrading process is 
vital to maintain homeostasis, turnover and quality control of cellular compartments, and in 
avoiding accumulation of damaged and surplus compartments and proteins, which can become 
toxic for the cell. Nutrient deprivation, hypoxia, reactive oxygen species, damaged DNA, 
protein aggregates, damaged organelles, or intracellular pathogens are stress factors that can 
induce the autophagy process to reduce toxicity. Autophagy serves as a dynamic recycling 
system. It is important during starvation for the formation of new cellular building blocks 
(Mizushima and Komatsu, 2011). Autophagy sequesters marked substrates by enclosing them 
into a double-membrane vesicle called an autophagosome. The vesicle contents then become 
degraded through fusion with a lysosome. Autophagy can be both selective and unselective. In 
unselective autophagy, the bulk degradation process is important for cell energy homeostasis, 
whereas selective autophagy is important in organelle and protein quality control, in the defense 
against microbes, and for innate immunity and antigen presentation (Johansen and Lamark, 
2011, Mizushima and Komatsu, 2011). Autophagy is a multistep process requiring 
transcriptional and translational regulation to start initiation and formation of autophagosomes 
that matures and becomes degraded.  
1.4.2 The molecular machinery of autophagosome formation 
The autophagic process is divided into initiation-, formation-, maturation- and degradation 
(Figure 1.2) (Mizushima et al., 2011, Mizushima and Komatsu, 2011). The autophagic process 
is regulated of autophagy-related (ATG/Atg) proteins. The ATG/Atg proteins are essential for 
the autophagic process. So far, at least 35 ATG genes have been identified, through yeast 
genetic studied, and 15 of these are core ATG genes, which are essential for the different 
autophagy pathways (Nakatogawa et al., 2009). Atg proteins are activated by different stress 
factors and make up different complexes.  
 
The autophagosome formation is regulated by different signaling pathways, including growth 
factors, such as IGF1, and hormones. These signals further regulate the proteins in the pathway. 
For example, the mammalian target of rapamycin complex 1 (mTORC1) is known to inhibit 
the autophagy initiation. mTORC1 and AMPK regulates autophagy by phosphorylating of the 
ULK1 kinase,. They do this by directly phosphorylating ULK1 at different positions, which 
induces different effects. AMPK phosphorylates and activates ULK1, while mTORC1 
phosphorylates and inactivates ULK1 (Kim et al., 2011). The autophagosome transport and 
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fusion is dependent on different regulators, which regulate adaptor proteins to bind to 
membranes and motor proteins.  
 
In figure 1.2 the autophagy process is described for the mammalian system. Induction of the 
phagophore begins with the activation of the Unc-51- like kinase (ULK) complex 1/2. ULK 1/2 
is activated together with FIP200, Atg13 and Atg101. This complex regulates the class III 
phosphatidylinositol 3-kinase (PI3K) complex (Vps34, Vps15, Beclin1, Atg14L and Ambra-
1). Vacuolar protein sorting protein 34 (Vps34) produces phosphatidylinositol 3-phosphate 
(PI3P) by phosphorylating the phosphatidylinositol’s. PI3P serves as an affinity membrane 
binding tag and recruits PI3P binding motifs (e.g.FYVE, Phox (PX) or PROPPIN- domains) 
(Lemmon, 2008). The formation of PI3P by PI3K initiates the nucleation step and formation of 
a cup-shaped double-membrane structure, known as the phagophore. The phagophore is 
established from either endoplasmic reticulum (ER), mitochondria, the Golgi apparatus or the 
plasma membrane (Tooze and Yoshimori, 2010, Mizushima et al., 2011, Hailey et al., 2010, 
Ravikumar et al., 2010). PI3Ps recruits different effectors, such as WIPI 1/2 (WD-repeat PI3P 
effector protein). WIPI2 binds directly to Atg16L, which is bound to the conjugate Atg5-Atg12 
(Dooley et al., 2014). The Atg12 conjugation system (Atg12, Atg7, Atg10, Atg5 and Atg16) 
interacts with the LC3 conjugation system (LC3A/B/C or GABARAP; GABARAPL1 and 
GABARAPL2/GATE-16) (Atg8 in yeast). LC3 becomes processed by Atg4 (cysteine protease) 
and the E2-like protein Atg3 is recruited by the Atg12 conjugate system, and lipidated LC3-I 
to LC3-II. LC3-II is conjugated to the lipid phophatidylethanolamine (PE) by the E1-like 
enzyme Atg7, which binds to the phagophore (Mizushima et al., 2001) (formation step). This 
conjugation results in the LC3 insertion into the inner and outer phagophore. LC3 serves as a 
receptor for selective autophagic receptors (i.e SQSTM1/p62 and NBR1) (Noda et al., 2010). 
These receptors direct marked substrates for degradation by their interaction with LC3. The 
phagophore become closed into an autophagosome. This autophagosome becomes fused with 
the lysosome and becomes an autolysosome (Johansen and Lamark, 2011)(maturation step). 
The substrates are degraded by lysosomal hydrolases, and are subsequently recycled back to 




Figure 1.2: The overall mechanism of the mammalian autophagy process. Unc-51- like kinase (ULK) 
complex 1/2 becomes initiated by different stress factors and regulates the Class III phosphatidylinositol 3-kinase 
(PI3K) complex. Class III PI3K complex induces the formation of the nucleation site where the phosphatidyl-
inositol becomes phosphorylated to PI3P. The formation of double membrane structure, phagophore, develops and 
WIPI proteins can be recruited. LC3 from the LC3-cpnjugation system attaches to the outer and inner side of the 
phagophore. Atg12--Atg5-Atg16L conjugate systems continues the formation of the phagophore. Derivative 
substrates are subsequentlys delivered to autophagy receptor, such as p62 or NBR1, which bind to LC3 on the 
inner side of the phagophore. The phagophore closes and becomes the autophagosome. The matured 
autophagosome fuses with the lysosome, and becomes the autolysosome. Here, all substrates become degraded.  
 
1.5 FYVE and coiled- coil domain containing 1 (FYCO1)  
FYCO1 is found as a single copy gene in humans, located in the putative tumor suppressor 
region on chromosome 3p21.3, called the"common eliminated region 1 ", C3CER1 (Kiss et al., 
2002) is 1478 amino acids (aa) long and contains an N-terminal RUN (RPIP8, UNC-14, and 
NESCA) domain, a long coiled-coil (CC) region, a FYVE (Rab1, YOTB, Vac1 and EEA1) 
domain, a LIR (LC3 interacting Region) region, and a C-terminal GOLD (Golgi dynamics) 




Figure 1.3: Domain architecture of human FYCO1. FYCO1 is divided into RUN-, Coiled-coli-, FYVE-, 
LIR region and GOLD domain.  Kinesin- 1 binding requires the Coiled-coil, Rab7 requires the N-terminal part of 
FYVE-domain, PI3P requires the FYVE domain and LC3 binds to FYCO1`s LIR domain between amino acids 
1276-1394.  
8 
There are proteins that share domain similarity with FYCO1 (Figure 1.3), and these proteins 
share similarities with their domain architecture as well. Two asuch proteins are presented in 
figure 1.4: the RUN and FYVE domain contain proteins (RUFY) and Early Endosome 
Antigen1 (EEA1) (Figure 1.4) (Rose et al., 2005). These are both associated with vesicles 
(Kitagishi and Matsuda, 2013). The PI3P lipid-binding domain (FYVE domain) on the C-




Figure 1.4: The alignment of the two homologue proteins of FYCO1. RUN-domain, RUN and 
FYVE domain contain protein 1(RUNFY1) and Early Endosome Antigen1 (EEA1).  Recreated from Pankiv et 
al (Pankiv et al., 2010).  
 
1.5.1 The functional role of FYCO1 
Previous study of FYCO1 revealed its role in transport of vesicles such as late endosomes (LE), 
autophagosomes and autolysosomes (Pankiv et al., 2010). The function of its RUN domain is 
still unknown, however it is predicted, through knowledge about similar proteins (RUFY 1-4), 
that it may facilitates interaction between FYCO1 proteins and Rab, and Rap proteins 
(Callebaut et al., 2001, Recacha et al., 2009). The RUN-domain of RUFY proteins have been 
suggested to be involved in membrane trafficking and cell polarity. This could suggest that 
proteins containing a RUN- domain can interact with filamentous networks, such as actin or 
MT (Kitagishi and Matsuda, 2013). FYCO1 dimerizes by its long CC region (Pankiv et al., 
2010). The FYVE domain interacts with PI3P, which is essential for its membrane recruitment 
(Gaullier et al., 1998). In addition, the C-terminal part of the CC region (FYCO1990-1233) 
(adjacent to FYVE domain) is found to interact with Rab7, which is responsible for LE and 
lysosome membrane recruitments (Pankiv et al., 2010). These vesicles contain p62/SQSTM1, 
which co-localizes with the lysosome marker LAMP1 and Atg5. This reveals the presence of 
FYCO1 on the outer membrane of autophagosomes and autolysosomes (Pankiv et al., 2010). 
The LIR region of FYCO1 (1276-1294 amino acids) was found to be essential for LC3B 
9 
interactions (Pankiv et al., 2010). FYCO1 was previously thought to have membrane tethering 
functions, and a mechanism for its selective autophagosomal membranes recruitment. 
However, more recently, FYCO1 was identified as an LC3 and Rab7 effector protein, which 
enables the MT plus-end directed transport of vesicles (Figure 1.5) (Pankiv et al., 2010).   
 
 
Figure 1.5: Illustration of the supposed role of 
FYCO1. A model of the proposed function of FYCO1 in 
vesicle trafficking along microtubule. The figure is 












Congenital cataracts (CC) is the cause of vision loss in approximately one third of infants born 
blind (Robinson et al., 1987). Interestingly, mutations in FYCO1 have been identified, which 
could be a cause of autosomal-recessive congenital cataracts (arCC). Most of the mutations 
resulted in truncated forms of the protein and caused termination of the peptide chain before 
the GOLD domain. One of these mutations is a homozygous single base change from leucine 
to proline in exon 16, position 1376, which is located in the GOLD domain. This mutation was 
identified to affect the transparency of the lens. This highlights a role for FYCO1 in human lens 
development and transparency (Chen et al., 2011). Another study revealed a direct recruitment 
of FYCO1 to Dectin-1 phagosomes by LC3 (Ma et al., 2014). FYCO1 co-localize with LC3B 
to Dectin-1 phagosomes and facilitates the maturation of early p40phox+ (early endosome 
marker) phagosomes into LAMP1+ phagosomes (Ma et al., 2014). Interestingly, FYCO1 is 
found to be working together with the ER-protein, protruding, in mediating microtubule-
dependent transport of LE via ER-endosome contact sites, which results in cell protrusions and 
neurite outgrowth (Raiborg et al., 2015). In the same year, Olsvik showed that FYCO1 contains 
a C-terminal LIR domain. This LIR domain contains an acidic residue on position 8 and a 
hydrophobic residue on position 9, which were found to be important for its efficient binding 
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to LC3B. Therefore this LIR-domain facilities the efficient maturation of autophagosomes 
during basal autophagy conditions (Olsvik et al., 2015). In previous studies, the expression of 
FYCO1 resulted in accumulation of lysosomes at the cell periphery, which is part of the 
indication of its lysosomal transport abilities (Johnson et al., 2016). Today, the function of the 
GOLD domain of FYCO1 is still unknown, but further studies may hopefully reveale its role. 
1.5.2 The GOLD domain 
The Golgi complex plays a key role in the modification and sorting of proteins received from 
the ER. Several eukaryotic golgi- and lipid-traffic proteins are involved in these processes and 
have a GOLD (Golgi dynamics) domain. The size of the GOLD domain is between 90 and 150 
amino acids long and is conserved in other proteins, as such as p24 family proteins, Sec14-like 
proteins and GCP60 (Anantharaman and Aravind, 2002). The predicted structure of the GOLD 
domain of FYCO1 was obtained from Phyre2 database (Kelley et al., 2015) was showed to be 





GOLD domain containing proteins 
p24 family proteins are highly conserved type 1 transmembrane proteins (TMED1), containing 
a GOLD domain (Schuiki and Volchuk, 2012). The p24 family consists of heterotetramer 
proteins, which contain a GOLD domain in their N-terminus, next to the CC-region. Ten p24 
proteins have been identified in in most vertebrates (whereas one is a pseudogene in humans) 
and they are divided into the four subclasses: p24α, β, γ and δ (Strating et al., 2009, Schuiki and 
Volchuk, 2012). They have a central role in protein transport from ER to Golgi. In addition to 
retrieval of escaped cargo and recycling of essential components via the retrograde pathway 
(Schuiki and Volchuk, 2012). The GOLD domain of p24γ2 was thought to interact with 
Figure 1.6: Graphic illustration of the GOLD 
domain of FYCO1. A graphic illustration over the two 
dimensional structure of the β-barrell strands of the 
GOLD domain, obtained from Phyre2 (Kelley et al., 
2015)The predicted structure of the GOLD domain of 
FYCO1 was showed to be composed of six to seven 
compact all- β-strands. 
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glycosylphosphatidylinositol-anchored proteins (GPI-AP). However, recent studies showed 
that the GOLD domain is not involved in GPI recognition. Instead, the motifs in the membrane-
adjacent α-helical region of p24γ2 were found to be involved in the integration of these proteins 
into coat protein complex II-coated transport vesicles. These findings suggest that the function 
of the GOLD domain still is unclear for p24 (Theiler et al., 2014).  
 
The GOLD domain has been identified in other proteins, such as Sec14-like proteins, 
Transmembrane emp24 domain containing protein 1 (TMED1/p24 family protein gamma-1) 
and Golgi adaptor acyl coenzyme A (acyl-CoA) binding domain protein 3 (ACBD3/GCP60). 
A multiple sequence alignments from Clustal Omega (Sievers et al., 2011, Goujon et al., 2010) 
shows which amino residues are conserve through their GOLD domain (Figure 1.7). The amino 
acids composition of the different GOLD domains differs from each of the proteins. These 
GOLD domain proteins are often found together with fatty acid -, lipid- or sterol binding 
domains such as CRAL-TRIO, FYVE, pleckstrin homology (PH), acetyl CoA- and oxysterol 




Figure 1.7: Alignment of the protein sequences of GOLD domain containing proteins. A multiple 
alignment was obtained from Clustal Omega (Sievers et al., 2011, Goujon et al., 2010). The sequence alignment 
is of the GOLD domain of FYCO1, SEC14-like protein 2, ADCBD3/ GCP60 and TMED1 (type 1 transmembrane 
proteins, p24 family). * (asterisk) indicates positions which have a single, fully conserved residue. . (period) 
indicate conservation between groups with weakly similar properties-scoring ≤0.5 in the Connet PAM 250 matrix 
and : (colon) indicates conservation between groups of strongly similar properties - scoring > 0.5 in the Gonnet 
PAM 250 matrix. Color description of the residues: The magenta are basic-H residues, the red are small (small + 
hydrophobic and aromatic) residues, blue are acidic residues, green are hydroxyl + sulfyfryl + amino residues and 
grey are unusual amino/imino acids(European Bioinformatics Institute (EMBL-EBI), 2016).  
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Sec14-like proteins are involved in secretion. SEC14-like domain of supernatant protein factor 
(SPF) are involved in the sterol endo-synthesis. SPF is found in complex with 2,3- 
oxidosqualene. This ligand binding was enabled by the removal of its GOLD domain. These 
results suggest that its GOLD domain acts as a regulator (Christen et al., 2015). The GCP60 
protein is a peripheral protein, which interacts with the cytoplasmic C-terminal part of the Golgi 
integral membrane protein Giantin (Sohda et al., 2001). 
 
The functional role of the GOLD domain 
The complete function of the GOLD domain is still unknown, but a protein-protein interaction 
function was identified in some GOLD domain containing proteins (Anantharaman and 
Aravind, 2002).  
 
Previous studies have shown that the GOLD domain functions as a cargo binding site and that 
the GOLD domain is involved in more than only protein-protein interactions. There is evidence 
that GOLD domain containing proteins are involved in assembly of membrane-associated 
complexes and regulate the cargo assembly into membranous vesicles, as revealed by 
Anantharam and Aravind (Anantharaman and Aravind, 2002). The GOLD domain was 
previously observed in sugar- and lipid-binding proteins (Gaskell et al., 1995).  
 
Therefore, it was predicted that the GOLD domain function of FYCO1 is related to the GOLD 
domain function of other similar proteins. However, the GOLD domains can have different 
functions due to their composition of the amino acids, and where it is located inside the protein. 
The multiple sequence alignment (Figure 1.7) showed that GOLD domains are not identical in 
their amino acids distribution.   
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1.5 Mass spectrometry as a tool for protein identification 
Proteomics is defined as the large-scale study of the structure and function of proteins. Mass 
spectrometry (MS) has become one of the most used methods for identification and analysis of 
complex protein samples. MS-based proteomics has become easier to use for protein study, due 
to the ability to use gene and genome sequence databases (Aebersold and Mann, 2003). MS 
groups individual ions according to their mass and their total charge, carried out on ionized 





Figure 1.8: Illustration of the major components of a mass spectrometer. The ionization starts at the 
ion source, where the ions are transferred through the m/z analyzer, the detector and then the mass-to-charge-ratio 
is calculated in the computer.  
 
 
The entire system works in a vacuum. Before applying the protein samples for identification, 
all proteins have to be digested into small peptide fragments. This digestion is done by proteases 
most commonly trypsin. Trypsin is a serine protease that specifically cleaves peptide bonds at 
the C-terminal side of lysine- and arginine-residues (Olsen et al., 2004). These peptides are 
fractionated by a liquid-chromatograph (LC) and can be ionized by an electrospray ionization 
(ESI) (Fenn et al., 1989). The soluble protein sample is converted into a gas phase when it is 
sent into MS. The liquid-chromatography-MS (LC-MS) is used to measure the mass of each 
protein peptide. LC-MS/MS (Tandem MS) fragment peptides through collision-induced 
dissociation (CID) or high energy collision dissociation (HCD) (Vogeser and Parhofer, 2007). 
LC-MS/MS is used as an analytical tool to identify protein-sequences based on the molecular 
mass of the particle and/or fragments in a complex sample, and is today the most used method 
in MS-based proteomics to analyze complex peptide mixture (Aebersold and Mann, 2003).  
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Protein identification is generally done through the use of already known protein sequences 
from a protein databases. Universal protein resource (UniProt) (Consortium, 2015) was used as 
the database for protein identification in the current study (UniProt, 2016). Each MS/MS 
spectrum uses their fragment spectrums to identify a specific protein. All of these spectrums 
have to correlate with the same protein. The value of the confidence depends on the correlation 
with the peptide amounts. The high heterogeneity produced by MS/MS data makes up for the 
limitation of its protein identification. Peptide fragments are identified through a database that 
compares the peptide fragments and a software is subsequently used to collect the protein data 
and develop a list over all protein candidates identified by LC-MS/MS. In the current study, 
Proteome Discover 2.1 Software (Thermo Scientific™) was used for protein identification.  
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1.6 Aims of study 
The initial aim of this study was to reveal and identify new protein interaction candidates for 
the RUN- and the GOLD domain of FYCO1. This would give us a greater insight over the 
complete function of FYCO1. However, RUN domain was excluded, because of technical 
problems and time limitations. Therefore, the GOLD domain became the major focus. A 
mutation in the GOLD domain (L1376P) was observed in patients with autosomal-recessive 
congenital cataracts. We were interesting if this mutation affected the expression level and the 
cellular localization of the isolated GOLD domain.  
 
By addressing the following questions, we hope to obtain a better understanding and 
determination of the full-length FYCO1s ability to interact with other proteins through its 
GOLD domain and how the mutation affects the localization and expression of the isolated 
GOLD domain in cells. 
 
 Is the GOLD domain involved in protein-protein interactions?  
 Which proteins do the GOLD domain interact with?  
 Are these direct or indirect interactions?  
 Does the transiently transfected GOLD domain redistribute some of the co-transfected 
putative protein partners?  
 How does the L1376P mutation affect the expression and localization of the isolated 
GOLD domain?  
  
16 
2. Materials and methods  
2.1 Materials  
Table 2.1: Plasmids and expression constructs 
Vectors Description Source 
Gateway cloning vectors 
pDest-EGFP-C1 Mammalian EGFP fusion expression 
vector; CMV promoter, Ampicillin 
resistant. Located at the N-terminal end. 
(Lamark et al., 2003) 
pDest-mCherry-C1 Mammalian mCherry fusion expression 
vector; backbone as pDest-EGFP-C1 
Ampicillin resistant. Located at the N-
terminal end. 
(Pankiv et al., 2007) 
pDest-myc-C1 Mammalian myc-tag fusion expression 
vector; CMV promoter ant T7 promoter, 
Ampicillin resistant. Located at the N-
terminal end. 
(Lamark et al., 2003) 
 
Vectors Description Source 
cDNA constructs made by site-directed mutagenesis and  
Gateway® LR reaction 
pENTER-FYCO1 
(1333-1478) 
Gateway® Entry vector for the GOLD 
domain of FYCO1 
(Pankiv et al., 2010) 
pENTER-FYCO1 
(1333-1478) L1376P 
Made by site-directed-mutagenesis of 
pENTER- FYCO (1333-1478) 
In this study 
pDONOR221-
RUVBL2 
Gateway® Entry vector Harvard Plasmid 
Repository 
pDONOR221-TUBA4 Gateway® Entry vector Harvard Plasmid 
Repository 
pDONOR221-DNAJA Gateway® Entry vector Harvard Plasmid 
Repository 
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Gateway® Entry vector Harvard Plasmid 
Repository 
 
Vectors Description Source 
Other vectors 
pDestEGFP-VPS4  (Bishop and 
Woodman, 2000) 
pDest-Myc-MO1B  In this study 
pDest-Myc-GBAS  In this study 
pDest-Myc-
NIPSNAP1 
 In this study 
pDestEGFP-
FYCO1(1-1478)  
Full-length FYCO1 (Pankiv et al., 2010) 
pGEX-4T-1 Bacterial GST fusion expression vector 
with a tac promoter. Used as an control  
In this study 
EGFP-KDEL ER marker In this study 
 
Table 2.2: cDNA constructs made by Gateway® LR reaction (this study) 
Vectors Description 
cDNA construct used in this study, made by Gateway® LR reaction  
pDest-15-FYCO1(1333-1478) From pENTR- FYCO1( 1333-1748) 
pDest-EGFP-FYCO1(1333-1378) From pENTR- FYCO1( 1333-1748) 
pDest-EGFP-FYCO1(1333-1378) L1376P From pENTR- FYCO1( 1333-1748) 
L1376P 
pDest-mCherry-FYCO1(1333-1378) From pENTR- FYCO1( 1333-1748) 
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pDest-mCherry-FYCO1(1333-1378) L1376P From pENTR- FYCO1( 1333-1748) 
L1376P 
pDest-myc- RUVBL2 From pDONOR221-RUVBL2 
pDest-myc-TUBA4A From pDONOR221-TUBA4A 
pDest-myc-DNAJA1 From pDONOR221-DNAJA1 
pDest-myc-TXNDC5 From pDONOR221-TXNDC5 
pDest-myc- ARF4 From pDONOR221-ARF4 
pDest-mCherry-RUVBL2 From pDONOR221-RUVBL2 
pDest-mCherry-TUBA4A From pDONOR221-TUBA4A 
pDest-mCherry-TXNDC5 From pDONOR221-TXNDC5 
 
Table 2.3: Primers for site-directed mutagenesis  














Note: In this study all plasmid constructs made by site-directed mutagenesis or gateway® LR 
reaction were verified by restriction digestion and/or DNA sequencing.  
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Table 2.4: Sequencing primers 
Primer name  Primer sequence Information 
M13 Forward 5`-GTTTTCCCAGTCACGACGTTGTA-3` Used in this study to sequence 
inserts in pDONOR221 
M13 Reverse 5`-GCGGATAACAATTTCACACAGGA-3` Used in this study to sequence 
inserts in pDONOR221 
ENTR 3` 5`-GATTTTGAGACACGGGCCA-3` Used in this study to sequence 
inserts in pENTR223 
ENTR 5` 5`-GTTAGTTACTTAAGCTCGG-3` Used in this study to sequence 
inserts in pENTR223 
GST-C1  5`- CATGGTCCTGCTGGAGTTCGTG-3` Used in this study to sequence 
inserts in pDest-EGFP 
 








Table 2.6: Antibodies (Ab) used for Immune fluorescence and IP 
 Antibody Supplier Dilution 





Sigma   1:2000 
Mouse anti- myc 
#MM-0169 
Medimabs  1:200 
DRAQ5™ BioStatus 1:2000 
Secondary Ab Alexa Fluor® 647  Life technology 1:1000 







BsrGI TGTACA 10.000  Neb 2.1 New England 
Biolabs 
HindIII- HT AAGCTT 20.000  Cutsmart New England 
Biolabs 
SacI GACGCTC 20.000  Cutsmart New England 
Biolabs 
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Goat-anti mouse  
Alexa Fluor® 555 
Goat-anti mouse 
Life technology 1:1000  
 

















Escherichia. coli  Description 
DH5α E.coli strain used for storage of 
plasmids 
SoluBL21 (DE3)  Strain used for protein 
expression 
Antibiotic Concentration (µg/ml) 
Ampicillin (amp)  100  
Kanamycin (kan) 50 
Spectinomycin 50 
Gentamycin  10 
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Table 2.9: Cell lines and their growth medium and buffers 
Cell line Description Full Growth 
medium (FM) 
HEK 293 Flp-In™ T-
REx cells (Invitrogen 
# R78007) 
 
Human embryonic kidney cells with Flp-In™ T-REx 
system. This cell line is design for rapid generation of a 
stable expression of a protein of interest by an Flp-In™ 
expression vector and a tetracycline-inducible expression 















HEK 293 Flp-In ZnF- 
FYCO1  
#12 
Human embryonic kidney cells  
These cells are knockout for full-length FYCO1 by Zink 
finger system. 


















Human embryonic kidney cells  
These cells are stably expressing GFP-FYCO1 controlled 
















 (ATCC® CCL-2™) 






























A        B       C   
Figure 2.1: Molecular weight ladder for DNA and proteins: A: 1 kb DNA ladder (Neb, #N3232L). B: 
SeeBlue®Plus2 Pre- Stained Protein Standard (Thermofisher scientific, # LC5925) for visualize proteins on SDS-




2.2.1 Overview of the study 
In the first part of the project, we sought to identify protein interactors binding to the GOLD 
domain of FYCO1 (amino acids 1333-1478), using affinity purification coupled to mass 
spectrometry (MS). Recombinant GOLD domain (1333-1478) of FYCO1 fused with a GST-
tag was expressed in competent E.coli strain, soluBL21™ (AMS Biotechnology). The GST-
GOLD domain was purified through pulldown with Glutathione sepharose beads. The 
interaction study was done using extracts from HeLa and HEK293 Flp-In T-REx cells. These 
cells were grown in full media, and lysed for in vitro pulldown assay. The pulldown assay was 
done with GST-bound GOLD domain to detect protein-interactors. The possible protein-
interaction-candidates were obtained by proteomics studies. In the second part of the study, 
these possible new protein-interaction-candidates were further studied through in vivo and in 
vitro study. 
2.2.2 Transformation of competent bacteria cells 
Bacteria transformation is the genetic alternation of bacteria, where competent bacteria take up 
naked DNA from the extracellular environment. This DNA becomes integrated into the genome 
or maintained as a plasmid. Transformation can occur naturally by closely related bacterias, but 
this process occurs at a slow rate. Certain bacteria can become competent by chemical or 
mechanical exposure. This treatment weakens the cellular membranes, which increases the 
efficiency of DNA uptake. Competent cells can be prepared through calcium chloride (CaCl2) 
or rubidium chloride (RbCl) treatment. Bacterias used in the current study are CaCl2 competent 
and prepared by laboratory technicians. 
The transformation procedure can be done by two commonly used methods, by either 
electroporation or heat shock. Both methods make pores in the plasma membrane for DNA 
uptake. In this current study, the heat shock procedure was used.  
Two different E.coli strains were used during this study: DH5α (Bethesda Research 
Laboratories Inc.) and SoluBL21 (DE3) (AMS Biotechnology (AMSBIO) (see description in 
the table 2.7). 
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Bacteria transformation procedure 
1. Competent bacteria cells were thawed on ice. 
2. 50 µl bacteria cells were mixed together with 100-150 ng plasmid (DNA of interest). 
The tubes were flicked 4-5 times to mix (do not vortex). 
3. The transformation mixture was held on ice for 20-30 minutes.  
4. The transformation mixture was incubated at 37⁰C (water bath) for 2 minutes.  
5. The transformation mixture was held on ice for 2 minutes. 
6. 500 µl catabolite repression (SOC) (room temperate) medium was added to the 
transformation mixture and incubated at 37⁰C for 1 hour with shaking.  
7. LB-agar plates (with required antibiotics) was moved from 4⁰C to room temperature.  
8. 250 µl of the transformation mixture were plated into the LB-agar plates with 
appropriate antibiotic and grown overnight at 37⁰C. 
9. The following day, three colonies were transferred into three cylinders with 5 ml LB 
media with appropriate antibiotics and regrown overnight for plasmid purification. 
Freezing stocks were made from these overnight cultures. 
 
Procedure for freezing down bacteria cells 
1. One colony was transfer to 5 ml pre-warmed LB medium with appropriate antibiotics 
and incubated overnight at 37⁰C. 
2. 1.2 ml overnight bacteria culture was mixed with 300 µl sterilized 50% Glycerol 





Super optimal broth with 
Catabolite repression (SOC) media 
20 g Bacto Trypton 
5 g Bacto yeast extract 
10 ml 250mMKCl 
5 g MgCl2 
20 mM glucose 
dH2O to 1 L 
pH adjusted to 7.5 with NaOH 
LB (Luria-Bertani)-  agar plate  
10 g Bacto Trypton 
5 g Bacto yeast extract 
10 g NaCl 
15g Agar 
dH2O to 1 L 
pH adjusted to 7.5 with NaOH 
 
LB medium  
10 g Bacto Trypton 
5 g Bacto yeast extract  
10 gNaCl 
dH2O to 1 L 
pH adjusted to 7.5 with NaOH 
Antibiotic: 
100 µg/ml Ampicillin  
50 µg/ml Kanamycin 
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2.2.3 Plasmid purification  
Plasmids from bacteria cells were purified by GenElute™ Plasmid Miniprep system (Sigma, 
#PLN350). Through this purification system, plasmid DNA is purified by an alkaline 
denaturation of high molecular weight chromosomal DNA, wherein the closed circular plasmid 
DNA remains double stranded, and through neutralization it becomes a part of the supernatant. 
The chromosomal DNA renatures and remains as pellet in the tube, while small and large 
plasmid DNA in the supernatant is extracted (Birnboim and Doly, 1979). The plasmid DNA is 
absorbed onto a silica membrane in the presence of high salts, where it is washed. After 
washing, the bound plasmid DNA becomes eluted in a Tris-EDTA buffer (Sigma). 
Procedure for GenElute™ Plasmid Miniprep kit (Sigma Aldrich)  
1. Cells were pelleted from 1-3 ml overnight culture by centrifuge at ≥12.000xg for 1 
minute. The supernatant was discarded. 
2. Cells were suspend cells inn 200 µl resuspension Solution by pipetting.  
3. 200 µl Lysis solution was added and the tubes were invert gently to mix. The reaction 
mixture were incubated for ≤ 5minutes. 
4. 350 µl Naturalization Solution (S3) was added to the solution.  
5. The cell solution was pelleted by centrifugation at ≥12.000xg for 10 minutes. 
6. 500 µl Column preparation Solution was added to the binding column in a collection 
tube. It was centrifuged at ≥12.000xg for 10minute. The flow- through was discarded. 
7. The cleared lysate from step 5 was transferred into the binding column. 
8. The binding column was centrifuged for 1minute. The flow- through was discarded. 
9. For optimal (EndA+ strains only) wash: 500µl Optional Wash Solution was added to the 
binding column. Centrifuged for 1 minute. The flow- through was discarded. 
10. 750µl Wash Solution was added to the binding column. Centrifuged for 1 minute. The 
flow- through was discarded. 
11. The empty binding column was centrifuged for 1-3minute  
12.  The purified plasmid DNA was eluted by transferring binding column into a new 
collection tube. 
13. 50-100µl Elution Solution was added to the binding column. The tube were incubated 
for 1-5minutes. Centrifuged for 1 minute.  
14. The DNA concentration was measured.  
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2.2.4 Measurement of DNA concentrations 
DNA concentration (ng/µl) from the DNA purification was measured by a Nanodrop 
2000/2000c Spectrophotometer (Themo scientific). Elution buffer was set as blank. The 
absorbance spectrum for nucleic acids are at 260 nm, and therefore the DNA concentration was 
quantified at this absorbance. However, proteins have absorption at 280nm, and peptide bonds 
absorbs at 230 nm. Protein and peptide bonds contaminate DNA samples and therefore the 
purity indication of the DNA samples are measured by the 260/280 nm and 260/230 nm ratios. 
DNA samples are pure when the ratio 260/280 nm is between 1.7-1.9 and the ration of 260/230 
is between 2.0-2.2.  
2.2.3 Agarose gel electrophoresis to identify DNAAgarose gel electrophorese separates DNA 
fragments based on their size. A 6X loading buffer is added to the DNA samples. The loading 
buffer makes the DNA sink into the well and their viability when they migrates through the gel. 
DNA fragments migrate through the agarose gel matrix, composed of agarose (here used 0.7%), 
a linear polysaccharide (originally extracted from seaweed), which together polymerizes into a 
compact network with different size of the pores (depending on the agarose concentration). 
These pores alter the migration speed of each DNA fragment. This migration is depend on the 
ions in the minigel-buffer, which carries the current through the electric field. This current 
creates the movement of DNA through the gel. DNA fragment migrates toward the positive 
pole (anode), due to their negative charge. The degree of migration depends on the size and the 
conformation of DNA fragment, but also together with the agarose concentration and the 
voltage. DNA fragment becomes visualized by a GelRed™ Nucleic Acid Gel stain (10000X) 
(Biotum) and the use of UV trans-illuminator UVP (BioDoc-it™ imaging system).  
Agarose gel Procedure 
0.7% agarose gel solutions was made by adding 0.7g SeaKem® LE Agarose (Lonza) in 100 ml 
minigelbuffer (1X), this solution was microwaved and gently shaken until all agarose powder 
were dissolved. The solution was poured into a chamber and the wells were placed into the 
solution. The solution was incubates for around 30 min at room temperature. The solution 
became polymerized and transformed into a gel. The gel was transferred into a tray, with 








2.2.5 Restriction enzyme digestion  
Restriction enzyme digestion is used to verify the DNA insert after DNA cloning. Recognition 
cutting of restriction sites on each side of the DNA insert is done to verify that the right insert 
has been cloned into the vector of interest. According to the restriction sites, one or two 
restriction enzymes are used for this approach. One restriction enzyme linearizers the vector. 
The band size that appear on the gel can be compared with the band size of vector without the 
insert. However, the insert can be cut out by two restriction enzymes. These two enzymes cut 
on each side of the insert or in a known site inside the insert. The verification is done when the 
digestion mix is run on an agarose gel, where the DNA construct and vectors is separated by 
size. If the band size correlates with the known size of the given insert appears, the cloning 
procedure has been successful. 
Restriction enzyme digestion protocol 
1. The following components of the reaction digestion mixture were mixed in a 1.5 ml 
Eppendorf tube: 
700 ng DNA construct 
1.5 µl Restriction buffer (From table 5) 
0.5 µl of each restriction enzyme (From table 5) 
dH2O to a final volume of 20 µl 
2. The digestion mixture was incubated a 37 ⁰C for 1 hour.  
3. The reaction was inactivated by adding 4 µl of 6X loading buffer and run on a 0.7% 
agarose gel.  
4. Bands were visualized by GelRed™ Nucleic Acid Gel stain (Biotum). 
  
6X gel loading buffer 
0.25% Bromphenol Blue (Merck) 
60 mM EDTA pH 8.0 





193.76 g Tris 
27.33 g NaOAc 
14.9g EDTA 
dH2O to 2 liters 












2.2.6 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) is used for cloning and amplifies the DNA sequences of 
interest. This method can be used in many different arrays of biochemical processes. Some of 
these can be DNA amplification, real-time quantification of nucleic acids, mutagenesis, 
sequencing, microRNA analysis, single nucleotide polymorphism (SNP) genotyping and viral 
quantification. 
The basis for every PCR reaction is the heat stabile DNA polymerase, free deoxynucleotides 
(dNTPs), DNA- primers and a suitable buffer. The PCR reaction consist of different steps. The 
first step break and denatures the double stranded DNA (dsDNA) helix by a heat shock (94-98 
⁰C). In the second step, the temperature is lowered (50-60 ⁰C) and the primers can anneal to the 
5`end of the single stranded DNA (ssDNA) (the temperature is depended on the melting 
temperature of the primer). In the third step, the temperature is raised to the optimum 
temperature (around 70 ⁰C) of the DNA polymerase. The DNA polymerase binds to the ssDNA 
and extends the ssDNA through the primers from 5`to 3` and attaches complementary dNTPs 
to the original DNA strand as a template. Step 1 to 3 are repeated multiple times and the target 
sequence is amplified at an exponential manner. The temperature is then lowered (4 ⁰C), as the 
final reaction step. 
2.2.6.1 PCR based Site-direct mutagenesis 
PCR based site- direct mutagenesis is a technique used to create mutations in the DNA sequence 
by PCR reaction. The designed primers contain a desired mutation. These primers are used as 
template for synthesizing the complementary strand with the mutation. Throughout this work 
the QuickChange® Site-Directed Mutagenesis Kit, instruction manual (Stratagene, #200518) 
was used to insert the wanted mutation.  
  
6X gel loading buffer 
0.25% Bromphenol Blue (Merck) 
60 mM EDTA pH 8.0 





Site-directed mutagenesis protocol 
1. The following were added in a PCR tube and mixed:  
1.5 µl of 10X reaction buffer 
1 µl (10ng) of dsDNA template (pENTER- FYCO1(1332-1478)) 
0.5 µl DMSO (sigma) 
1 µl (10 µM) Primer forward (From table 3) 
1 µl (10 µM) Primer revers (From table 3) 
2.5 µl dNTP mix (Sigma) 
dH2O to a final volume of 25 µl 
2. 0.5 µl pfuTurbo DNA polymerase (2.5U/ µl) (Agilent Technologies, #600254-52) were 
added to the mixture  
3. The reaction was placed in a PCR cycler (Eppendorf AH diagnostics) with the following 
PCR program (Table 2.10). 
 













Numbers of Cycles Temperature (⁰C) Time  
1 96 30 seconds 
18 96 30 seconds 
55 (primer Tm - 5⁰C) 1 minute 
68 2 minutes/kb  
Hold 4 ∝ 
10X Reaction Buffer 
100nM KCl 
100mM (NH4)2SO4 
200mM Tris-HCl (pH 8.8) 
20mM MgSO4 
1% Triton® X-100 
1 mg/ml nuclease-free bovine 
serum albumin (BSA) 
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2.2.6.2 PCR based DNA sequencing  
DNA sequencing is used to verify the precise order of nucleotides in the DNA, often used after 
cloning and mutagenesis. BigDye®3.1 kit (Applied Biosystems) was used with different 
primers according to their vectors.  
Procedure 
1. The following reagents were mixed into PCR tubes and held on ice.  
200-500 ng Plasmid 
1 µl BigDye Terminator v3.1 mix 
2 µl of 5X BigDye sequencing buffer 
1 µl Sequence primer (From table 4) 
dH2O to final volume of 10 µl 
2. The reagent mix were placed into a PCR cycler and run with following PCR program (Table 
2.11).  
3. The finished reagent mix was delivered to the core sequencing facility. 
 









Numbers of Cycles Temperature 
(⁰C) 
Time  
1 96 1 minute 
33 96 30 seconds 
50 15 seconds 
60 4 minutes 
Hold 4 ∝ 
32 
2.2.7 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS PAGE is a technique used to separate and identify proteins according to their size. These 
proteins are treated with an anionic detergent, SDS. SDS denatures secondary structures and 
non- disulfide liked tertiary structures and unfolding proteins (Shapoiro et al. 1976, weber and 
Osborn 2969). It also applies negative charge to the proteins, which makes them migrate 
towards the positive field. It is the glycerol in the SDS- loading buffer that enables the samples 
to sink into the well. Smaller proteins run longer than larger proteins. 
10% acrylamide gel procedure 
The following components were mixed in each Erlenmeyer flask.  
10% Separation gel (protein size identification for proteins between 25 kDa to 80 kDa).  
1. 4.9 ml dH2O 
2. 2.5 ml 40% Acrylamid (Applichem) 
3. 2.5 ml  4X Separation gel buffer 
4. 100 µl APS (Ammonuium peroxidsulfate) (Merck) 
5. 10µl TEMED (N,N,N',N'-Tetramethylethylenediamine) (Sigma) 
4 % concentration gel  
1. 6.4 ml dH2O 
2. 1.0 ml 40% Acrylamid (Applichem) 
3. 2.5 ml 4X concentration gel buffer 
4. 100 µl APS ( Merck) 












4X Separating gel buffer 
181.65 g Tris- base 
4g SDS 
dH2O to 1 liter 
pH adjusted to 6.8 with HCl 
 
4X Concentrating gel buffer  
60.55 g Tris- base 
4g SDS 
dH2O to 1 liter 
pH adjusted to 6.8 with HCl 
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2.2.7.1 Coomassie blue staining for polyacrylamide gels 
Coomassie blue (also known as brilliant blue) stain is used to visualize proteins after separation 
by SDS-PAGE. It creates electrostatic interactions with protonated basic amino acids and 
hydrophobic associations with aromatic residues inside polyacrylamide gels. This staining is 
compatible for MS.  
Procedure 
1. SDS- PAGE gel was removed out of the electrophoresis apparatus and into a 15cm 
plate. 
2. Fix solution was added for 10 minutes, discard fix solution.  
3. Staining solution (Coomassie Brilliant Blue R-250 (Thermo Scientific™) was added for 
1 hour. Coomassie Brilliant Blue R-250 was poured back to its tube.  
4. Destaining solution I was added for around 20 min. Destaining solution I was collected 
in a flask. 















Fix solution  
400 ml MeOH 
100 ml Acetic 
acid 
500 ml dH2O 
Staining solution  
62.5 ml Stain stock (2 g 
Coomassie Brilliant Blue R-250)  
250 ml MeOH 
50 ml Acetic acid 
dH2O to 500 ml 
Destaining solution I 
500 ml MeOH 
100 ml Acetic acid 
dH2O to 1 liter 
Destaining solution II 
50 ml MeOH 
70 ml Acetic acid 
dH2O to 1 liter 
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2.2.8 GATEWAY cloning technology 
Gateway® cloning technology is a cloning technique where the gene of interest (GOI) is clone 
into a vector, by recombination. The gateway cloning technique is based on the site-specific 
recombinant properties of bacteriophage lambda in E.coli, with the properties of switching 
between a lytic and a lysogenic life cycle. The site- specific integration of phage lambda into 
the host genome is gone in the latter life cycle (Hartley et al., 2000). These properties enables 
fast in-frame cloning. There are recombinant sequences called Gateway attachment (att) sites, 
where the GOI can be inserted. Two set of registered enzyme mixes are used in this cloning 
technique. These are called BP Clonase and LR Clonase. This Gateway method is divided into 
two steps. First, generation of Gateway entry clones. Here are specific Gateway attB1 and attB2 
sequences added to the 5` and 3`end of a GOI. These sequences are produced by a gene specific 
PCR primers. This sequence is inserted into a special Gateway plasmid called donor vector, 
done by BP Clonase enzyme mix. This mix catalyses the recombination and insertion of the 
attB sequence PCR product into the attP recombinant site in the Gateway donor vector called 
Gateway entry clone (pENTR, used for storage of gene constructs) which contain a Gateway 
attL recombinant site. In the second step, the gene cassette in the Gateway entry vector can be 
transferred into a Gateway destination vector (pDest) by LR Clonase enzyme mix. This pDest 
vector contain a Gateway attR recombinant sequence and other elements, as promoters and/or 
epitope tags, which alter the gene properties.  
LR reaction procedure 
The reaction mix was made in a 1.5 ml Eppendorf tube.  
1. The following components were mixed and incubated at 25⁰C (water bath) overnight or 
(2-3 hours): 
100 ng pENTER cDNA construct  
150 ng pDest vector 
0.5 µl LR (enzyme) (Invitrogen) 
TE buffer was added up to a total volume of 10 µl  
2. LR mixture was incubated with 1µl protease K (Biolabs) at 37⁰C for 10 minutes. 
3. 5 µl of the gateway mix was transformated into DH5α chemically competent E.coli cells 
for plasmid amplification and purification. 
All gateway constructs were verified by restriction digestion and runned on an agarose gel 






2.2.9 GST pull-down assay 
Glutathione S-transferase (GST) pull-down assay is a method used to study protein-protein 
interactions. These interactions are based on the proteins capability to bind to protein of interest. 
In this assay, the protein of interest must be linked to a GST-tag. GST-tagged proteins are 
expressed in large amount in E.coli by DNA recombinant technology (section 2.2.9.1). These 
proteins have high affinity for glutathione and can be purified by affinity chromatography on 
glutathione-Sepharose™ 4 Fast Flow beads (GE Healthcare).  Their interaction partners can be 
studied by an incubation of the GST-protein of interest together with a complex putative protein 
mixture. Any protein-interaction complexes can be recovered by centrifugation and washing 
and resolved by SDS-PAGE (Vikis and Guan, 2004). Verification of the putative protein 
interaction partners can be done by MS analyzation. Protein bands are cut-out and sent to the 
MS facility core for identification. However, in vitro translation of putative interaction partners 
by TNT® T7 Coupled Reticuloyte Lysate System (Promega) with radioactively labeled (e.g. 
[35S]-methionine) can be verified by autoradiography. Additional, unlabeled putative 
interaction partners can be verified by immunoprecipitation (IP) assay. 
During this study, GST pulldown- assay were done with both in vitro and in vivo translated 
protein interaction partners for the GOLD domain of FYCO1 (amino acids 1333-1478) fused 
to a GST-tag.  
2.2.9.1 Production of GST-fused proteins in E.coli 
The GOLD domain of FYCO1 was cloned into a pDest15- vector. This resulted in a GST-tag 
(220 amino acids) on the N-terminal part of the GOLD domain. pDest15 vector is a gateway 
vector for construction of GST fusion proteins. It contains a glutathione S-transferase- tag 
(GST-tag) and T7 promoter. SoluBL21 (DE3) E.coli strains are improved strains for producing 
soluble proteins with GST-tag under control of a T7 promoter. The transcription of the gene is 
induced upon adding isopropyl-β-D-thiogalactopyranoside (IPTG). IPTG inhibits a repressor 
(Lac repressor), which is bound to the T7 promoter. This repressor will fall off when IPTG 
bind. The T7 promoter becomes available for the T7 RNA polymerase, which binds and 
transcribes the target gene.  
Tris-EDTA (TE) buffer 
10mM Tris/HCl, pH 7.4 (adjusted with HCl) 
1mM EDTA pH 8.0 
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Protein expression procedure 
SoluBL21 (DE3) cells containing the required plasmid were plated out on an agar- plate with 
the required antibiotic. Each plasmid contains an antibiotic resistant gene, which enables the 
cells to grow on antibiotic plates.  
1. One colony was inoculated into 5 ml pre-warmed LB-media with amp and grown over-
night (approximately 16 hours).  
2. The over- night bacteria culture was transferred into 100 ml pre-heated 2xYT-media 
with ampicillin and grown for 2-3 hours at 37⁰C with shaking until it had an OD600nm 
value between 0.6-0.9.  
3. This pre-culture was induced by 50 µl 1M IPTG (Promega) 
4. The culture was incubated for 3-4 hours at room temperature (approximately 25⁰C) with 
shaking.  
5. The culture was pelleted by centrifugation at 5000 xg for 10minutes at 4⁰C.  
6. The supernatant was discard, and the bacteria pellet was kept on ice 
7. 4 ml of lysis buffer was added to the bacteria pellet.  
8. 10 % Triton X-100 (Sigma) was added and the bacteria solution was divided into tubes 












2xYT medium  
16 g Bacto trypon 
5 g Bacto yeast extract 
5 g NaCl 
dH2O to1 lire 
pH adjusted to 7.5 with NaOH 
20 mM glucose 




NETN buffer  
20mM Tris-HCl pH8.0 
100mM NaCl (2M) 
0.5% NP40 (Nonidet p 40 
Substrate) (sigma) (10%) 
1mM EDTA (0.5M) 
dH2O to final volume 
Lysis buffer 
50mM Tris- HCl pH 8 
250nM NaCl  
1mM EDTA 
1mM DTT 
0.35 mg/ml lysozyme 
 
LB medium  
10 g Bacto Trypton 
5 g Bacto yeast extract  
10 gNaCl 
dH2O to 1 L 
pH adjusted to 7.5 with NaOH 
Antibiotic: 
100 µg/ml Ampicillin  
50 µg/ml Kanamycin 
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Protein harvesting procedure 
1. The tubes with the lysed bacteria were thawed on ice. 
2. The cells were sonicated (Vibra-cell™, Sonics) at 40% amplitude, 3 times for 20 
seconds with 10 seconds pause in between.  
3. The sonicated solution was centrifuge at high speed for 10 minutes.  
4. The supernatant (periplasmic components, containing soluble proteins) was kept for 
protein purification  
 
2.2.9.2 Protein purification by GST-pulldown assay 
In this study, the pDest15-GOLD domain was bound to glutathione-sepharose beads by affinity 
chromatography. GST has a very strong affinity for glutathione and results in a strong binding 
between GST-fusion proteins and Glutathione Sepharose™ 4 Fast Flow beads (GE healthcare). 
Glutathione Sepharose™ 4 Fast Flow beads (GE healthcare) are dissolved in 20 % ethanol. 
Procedure 
1. 200 µl of Glutathione Sepharose™ 4 Fast Flow beads (GE healthcare) were taken out.  
2. The ethanol was discarded and the beads were washed three times with cooled NETN 
buffer. 
3. Protein lysate were added together with the beads and incubate the mix at 4⁰C for 1hour, 
rotating.  
4. The beads were spanned down and washed three times with 1X PBS (10X # 70011-050 pH 
7.4, Gibco /life technologies).  
5. The concentration of beds were adjusted to 50 % with 1X PBS (10X # 70011-050 pH 7.4, 
Gibco /life technologies) 
6. The beads were stored in 50% NETN buffer.  
7. 10 µl protein beads were taken out for verification by SDS-PAGE.  
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2.2.9.3 GST-pulldown assay for examine new protein interaction candidates for the 
GOLD domain 
Through this GST-Pulldown assay, protein interaction candidates from HEK293 T-REx Flp-
In - and HeLa cell lysates (section 2.2.10.4) were investigated. These cells were incubated 
together with both GST-GOLD proteins– and GST (negative control) bound to glutathione-
sepharose beads.  
Procedure  
1. Cell lysate from HEK293 Flp-In T-REx- and HeLa cells (~106-107 cells) (section 
2.2.10.4) were incubated together with 15 µl empty and washed glutathione-sepharose 
beads (50:50 NETN buffer) for 30 minutes at 4⁰C, rotating.  
2. The cell lysate were transferred to 15-20 µl washed (two times with NETN buffer) GST-
GOLD protein beads and GST beads and incubated for ~3 hours at 4 ⁰C, rotating. 
3. The GST-GOLD and GST beads were washed 5-6 times with NETN buffer. Discard 
buffer. 
4. 15 µl SDS-loading buffer were mixed with the beads and boiled for 3-5 minutes and 
centrifuged by a table centrifuge. SeeBlue®Plus2 Pre- Stained Protein Standard 
(Thermo Scientific™ # LC5925) ladder was used (Figure 1B).  
5.  The protein samples were separated by a SDS-PAGE (section 2.2.7).  
6. All protein bands were cut and sent to mass spectrometry (section 2.2.15) 
 
2.2.9.4 In vitro transcription and translation of proteins coupled to a GST-pulldown 
assay 
Direct protein-protein interaction using TNT™ T7 Coupled reticulocyte Lysate System (RTL) 
(Promega) where the in vitro transcribed and translated proteins were radioactive labeled, [35S]-
methionine). Here, direct interaction between the in vitro translated protein-interaction 
candidates and GST-GOLD were tested.  
Procedure from the Promega kit:  
The components of the reaction mixture (Promega kit) were mixed in a 1.5 µl eppendorf tube. 
One reaction mixture is enough for five samples. The reaction mixture was multiplied when 
more samples were made. 
1.  Following components (Promega kit)  for one reaction mixture were mixed:  
25 µl reticulocyte lysate 
4 µl TNT buffer 
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1µl amino acids mix minus methionine  
1µl [35S] - Methionine 
1µl TNT polymerase T7  
2. 1 µg DNA and dH2O were added to the total reaction mixture (32 µl) to the total of 50 
µl. 
3. The reaction mixtures were incubated at 30⁰C for 60-90 minutes.  
4. To verify the translation, 3 µl of the in vitro translation were taken out for each sample, 
mixed with 18 µl 2X SDS- loading buffer with 10 % DTT (1M) and boiled for 3-5 
minutes (Input).  
5. The rest of each in vitro translated protein sample were pre-incubated with 15 µl of 
empty GST-beads (washed with cooled NETN buffer) together with 100 µl of cooled 
NETN (containing protease inhibitor) for 30 minutes at 4 ⁰C, rotating.  
6. ~100 µl of each in vitro translated protein samples were incubated with 15-20 µl 50% 
GST-GOLD beads (washed with cooled NETN buffer) for 1 hound at 4 ⁰C, rotating.  
7. The beads were centrifuged by a table centrifuge, and washed five times with cooled 
NETN buffer.  
8. All of the NETN buffer were discard and 15 µl of 2X SDS- loading buffer with 10 % 
DTT (1M) (Sigma) were added. The samples were boiled for 3-5 minutes.  
9.  15 µl of the GST-pulldown and 3.5 µl of the pre-incubation (5 % input) reaction 
mixture was loaded on a 10% thin SDS-PAGE gel.  
 
2.2.9.4.1 Autoradiography: Detection of radioactive proteins in polyacrylamide gels  
The SDS-PAGE gel was transferred on a filter paper, covered with a sheet of plastic foil and 
dried in a GelDryer (BioRad, Model 583) at 80⁰C for 45`-1 hour. The dried gel was transferred 
inside a film cassette with a phosphor imaging plate (Fujifilm Science Lab) on top. The film 
was scanned the next day with FUJI BAS-5000. All images were detected by Image Gauge 












2.2.10 Mammalian cell culture  
Throughout this study putative protein interaction for the GOLD domain of FYCO1 were 
studied by use of mammalian cells from human cervix HeLa cells, human embryonal kidney 
(HEK) 293 Flp-In T-rex cells and human lens cells (B-3) (Table 2.9). 
2.2.10.1 Growth condition 
All mammalian cell cultures were grown in their full medium (FM) (Table 2.9) and kept in 
incubators with a temperature of 37⁰C, 95% air and 5% Carbon dioxide (CO2).  
2.2.10.2 Cell splitting 
Mammalian cells were kept in their full growth medium (FM), passage every third day (with a 
confluence between 80%), by dividing them 1/5, 1/10 or 1/20 (depends on the next splitting 
event)* into new flasks. The optimal confluence for transfection, freezed down or before 
pulldown assay is 70%. New cells were taken up after passage number 10 and 20, according to 
the cell-type. 
Cell passage procedure 
1. The FM of the cells were discarded. 
2. The cells were washed with room temperature 1X PBS (10X # 70011-050 pH 7.4, Gibco 
/life technologies) one time. Discard PBS. 
3. 0.5-1.5 ml pre-heated Trypsin-EDTA (Sigma) was added to the cells and incubated at 
37⁰C for 3-5 minutes. Or until they are detached to the surface.  
4. 5 ml pre-heated FM was added to the cells. The cells were suspend 5-10 times. 
NETN buffer  
20mM Tris-HCl pH8.0 
100mM NaCl (2M) 
0.5% NP40 (Nonidet p 40 
Substrate) (sigma) (10%) 
1mM EDTA (0.5M) 
dH2O to final volume 
 
Protease inhibitor: 
1 Complete protease inhibitor 
cocktail tablet (Roche) in 10 ml 
NETN buffer 
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5. Cells were transferred to a new flask with pre-heated FM. Split cells in a relation of 1:2, 
for each incubation day. 
 
*Alternation: B3 cells grow slower than the other cell lines and therefor have to split 1:5.  
2.2.10.3 Taking up cells and freeze them down 
Uptake of mammalian cell procedure  
All cells are stored in liquid nitrogen. Cells were taken up from the nitrogen tank and thawed 
gently. They were added into pre-heated FM in 75cm2 flask. They were either spanned down 
or incubated between 3-4 hours, before the FM was changed. This was done to avoid DMSO 
(sigma) to affect the cells (DMSO is toxic for the cell). Cells were incubated at normal condition 
and spitted with a confluence of 80%.  
2.2.10.3.1 Freezing down mammalian cells 
Cells were freezed down with a confluence of 70%. Important to keep the cells on ice during 
the procedure.  
Procedure:  
1. Cells were passage to get a less confluence than normal passage procedure.  
2. Cells were spanned down and re-suspended gently the pellet with cold freezing mixture 
(10% DMSO (Sigma) and 90%FBS ( Merck)) 
3. The cells were divide into 2 ml freezing tubes and stored in the nitrogen tank.  
 
2.2.10.4 Mammalian cell lysis 
4 x 106 cells/ml were seeded out on 15cm plates. 2ml of the lysed cells were incubated into the 
GST-pulldown assay. Cells were seeded out in a density and lysed to obtain all proteins for 
pulldown assay. The lysed cells were added together with beads containing bound GOLD 
domain.  
Cell lysis procedure 
1. The cells were washed two times in 1X PBS (10X # 70011-050 pH 7.4, Gibco /life 
technologies)  1ml cold cell lysisbuffer (with protease and phosphatase inhibitors) were 
added to the 15cm cell-plates. The plates were incubated for 20 minutes at 4⁰C, shaking. 
2. The cells were scraped and the lysates were transferred to a 2 ml Eppendorf tubes. 
Centrifuge it at 16000xg at 4⁰C. 











2.2.10.5 Mammalian cell transfection 
Cell transfection can be done by different transfection reagent. Transit®-LT1 (Mirus) and 
Metafectene®Pro (Biontex) were used in this study and are both liposome based transfection 
reagents. These reagents containing lipids, which capsulate DNA. The lipid capsulated DNA is 
taken up by the cell through endocytosis. 
Transfection procedure  
Cells were counted by a Bûrkner counting chamber. 7000-10 000 cells were seeded out into 8 
wells plates for microscopy one day before the transfection. The cell confluency were around 
70% before transfection. Cells were transfect the next day with the transfection mixture. 0.1µg 
DNA/well were added into the transfection mixture and incubate for 15-20 minutes at room 
temperature. FM were changed and 200 µl transfection mix were added to the wells. The cells 
were incubated at 37⁰C, with 95% air and 5% Carbon dioxide (CO2) over night.  Cells were 
Fixated the next day with 100% MeOH.  
Transfection mixture:  
26µl DEM/ well (÷p/s, ÷ FBS) and 0.5µl Transit®-LT1 (Mirus) / Metafectene®Pro (Biontex)/ 
well were mixed and incubate for 3-5 minutes at room temperature.   
Cell Lysisbuffer  
20mM Tris-HCl pH8.0 
100mM NaCl (2M) 
0.5% NP40 (Nonidet p 40 
Substrate) (sigma) (10%) 
1mM EDTA (0.5M) 
dH2O to final volume 
In 10 ml buffer 
1 tablet complete EDTA-free 
protease inhibitor (Roche) 






2.2.11 Fluorescence microscope 
A fluorescence microscope is an optical microscope, which uses fluorescence to study organic 
or inorganic substances. Fluorescence is define as an atoms ability to absorb light energy 
(excited) from a specific wavelength. The electron jumps to a higher energy level, a short-lived 
excited state. Here, the electron loose energy and goes back to the ground state, thereby emitting 
a photon. The emitted fluorescence can be used to generates an image (Lichtman and 
Conchello, 2005).A confocal microscope is one type of fluorescence microscope.  
2.2.11.1 Confocal microscope  
Confocal microscopes are specialized fluorescence microscope, which have high sensitivity, 
high signal to noise ratio and great specificity in excitation and emission detection. In addition, 
the lateral and vertical resolution is higher than in normal fluorescence microscope. The 
features are obtained by spatial filtering techniques, which eliminate out- of focus light and 
increase the brightness in fluorescence image of thick specimens.  Thick specimens can be 
optically sliced and be used to construct a 3D image. Confocal microscope employs point-by-
point illumination or point scanning.Two pinholes eliminates the out- of focus fluorescence 
emission light, and together with the point scanning generates images with great optical 
resolution. In laser scanning confocal microscopy (LSCM) the light source is a laser. LSCM is 
widely used today as an essential tool for biomedical imagining applications. This laser passes 
first through the first pinhole, called light source pinhole aperture. This pinhole is situated in a 
conjugate plane (confocal), with a scanning point on the specimen. A dichromatic mirror reflect 
the excited light rays, which becomes focused by the objective lens before it reaches the 
specimen in a focal plane. The fluorescence light becomes emitted from the specimen and 
passes through the objective lens, where it becomes focused. The focused light passes back 
through the dichromatic mirror and focused as a confocal point at the detector pinhole aperture.  
The light becomes detected by the photodetector (Wright and Wright, 2002).  
2.2.12 Cell fixing and staining 
Cell preparation for confocal microscopy is important and cells can be fixed by either methanol, 
acetone, ethanol, paraformaldehyde (PFA) or formalin. Methanol fixation was used during this 
study and is a more sensitive fixation and lower the risk to destroy specific cellular structures 
(e.g. ER).  
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Methanol fixation procedure 
1. Cells were fixed in -20⁰C methanol (100%) for 10 minutes. Collect the methanol. 
2. The cells were washed 3 times with ice-cold 1X PBS (10X # 70011-050 pH 7.4, Gibco 
/life technologies). 
3. The cells were stored in 1X PBS (10X # 70011-050 pH 7.4, Gibco /life technologies) 
 
2.2.12.1 Immunofluorescence staining procedure 
1. 200 µl block solution (3% goat serum in 1X PBS (10X # 70011-050 pH 7.4, Gibco /life 
technologies) were added onto the cells on the confocal wells.  
2. Incubate the cells with the blocking solution for minimum 30 minutes shaking at room 
temperature. 
3. 150 µl of the primary Antibody (Ab) (in 1% goat serum in 1X PBS (Gibco /life 
technologies # 70011-050 pH 7.4)) solution were added to each confocal well and 
incubated for minimum 30 minutes, shaking at room temperature. 
4. Wash the wells 6 times with ice-cold 1X PBS (Gibco /life technologies # 70011-050 pH 
7.4) 
5. 150 µl of the secondary Ab (in 1% goat serum in 1X PBS ((Gibco /life technologies # 
70011-050 pH 7.4)) (corresponding alexa-flour) solution were added into each confocal 
cell and incubated for minimum 30minutes, shaking at room temperature. It were keep 
dark. 
6. Keep the cells with 1X PBS (Gibco /life technologies # 70011-050 pH 7.4) at 4⁰C. 
 
2.2.13 GFP- trap /Immunoprecipitation  
Green fluorescent protein (GFP) tags are used to study proteins localization and dynamics. In 
addition, GFP fused proteins can be used for immune precipitation assays, enzyme activity 
measurements, ChIP analysis and MS, through a GFP –trap® system (Chromtek). This assay 
is used to analyze GFP proteins and their interaction candidates. GFP-Trap is composed of GFP 
binding proteins coupled to monovalent matrix (e.g. magnetic agarose beads, agarose beads, 
96-multiwell plate or magnetic particles). However, agarose beads were used in this study.   
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GFP –Trap and immune precipitation Procedure 
1. HEK294 Flp-In ZnF FYCO1 #12 and HEK294 Flp-In ZnF FYCO1#12  GFP-FYCO1 
cells were seeded out with a density of ~320.000 cells/ 6cm well.  
2. The cells were transfected with 4 µl Metafect® pro (Biontex) together with 300 µl 
DMEM (minus FBS and antibiotics), overnight.  
3. The gene expression of GFP- FYCO1 from the HEK294 Flp-In ZnF FYCO1 #12  GFP-
FYCO1 cells were induced by 1 µg/ml Tetracycline (Sigma). 
4. Harvest cells, all FM was aspirated and the cells were washed with 1X PBS.  
5. The cells were lysed by adding 300 µl RIPA buffer (+ inhibitors). Cells were incubated 
at 4⁰C, shaking for ~30 min.  
6. The cells lysate were scraped and centrifuged at 500g for 5 minutes.  
7. The cell lysate supernatant were kept on ice.  
8. 15 µl of supernatant were taken out as the input sample. Add 2X SDS-loading buffer 
(10% 1M DTT) to the input. Boil for 3-5 minutes. 
9. 12 µl 50% GFP-Trap® Agarose beads were prepared by washing them in 1X RIPA 
buffer. 
10. Each cell lysate supernatant were loaded on to 12 µl 50% GFP-Trap® Agarose beads 
and incubated  for 2 hour at 4 ⁰C, rotating.  
11. The beads were washed 3 times with 1X RIPA buffer.  
12. 15 µl 2X SDS-loading buffer were added to the beads and boiled for 3-5 minutes. 
13. The bound proteins from the beads were loaded onto a SDS- PAGE. 
 
2.2.14 Western Blot (WB)  
WB is a method where proteins are transferred from a gel to a membrane (e.g. nitrocellulose or 
polyvinylidene fluoride (PVDF)) by using an electric field. First, proteins are separated by SDS-
PAGE. Next, proteins are blotted to the membrane. After the blotting, the membrane is blocked 
with 5% milk to prevent any unspecific binding of antibodies to the surface of the membrane. 
Lastly, the membrane become incubated with primary antibodies, which is specific for the 
protein of interest. Next, the membrane is incubated with a secondary antibody (e.g. 
Fluorescence dye), to recognize the protein of interest.  
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WB Procedure 
1. The PVDF membrane was first sought in transfer buffer before the SDS-PAGE gel was 
added. The protein gel was blotted to the membrane by Trans-Blot® Turbo™ (BioRad). 
2. After the blotting, the membrane were blocked with a blocking buffer (5% milk 
(Normilk AS) in TBST for 1 hour at room temperature.  
3. Primary antibody was incubated overnight. 
4. The membrane was washed 3 times for 10 minutes each time with TBST buffer  
5. The secondary antibody were incubated for 1 hour at room temperature and washed 3 
times for 10 minutes each time with TBST buffer.  
6. The membrane signals were detected by a Lumi-Imager F1™ (Boehringer Mannheim), 










2.2.15 Protein identification by Liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) 
The identification of new protein-interaction for the GOLD domain of FYCO1 were tested by 
cell lysate pulldown assay followed by protein-identification by MS. Recombinant GOLD 
domain fused to GST was expressed in E. coli  and bound to GST-beads. A pulldown assay 
with cell lysate from HeLa and HEK293 T-REx Flp-In cells were incubated together with the 
GST-GOLD domain- and GST protein beads (section 2.2.9.3).   
RIPA buffer 




0.25 % Triton- X100 
TBST buffer 
10 mM Tris pH8  
150 mM NaCl 
1 mL Tween-20 
dH2O to total 1 L 
Transfer buffer 
1.88 g Tris base 
23.25 g Glycin 
150 ml methanol (100%) 
850 ml dH2O 
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Procedure 
1. Proteins from the GST-pulldown assay were resolved on SDS-PAGE (10% acrylamide 
gel) to the bands are in the separation gel (15-20 minutes at 30mA). 
2. The buffer was poured from the container, leaving the gel in the tray. 
3. All gel bands containing proteins were exited with a scalpel. Be careful for 
contamination of keratin.  
4. The gel piece were transferred to a protein LoBind Eppendorf tube.  
5. The protein gel-pieces were delivered to our proteomic core facility, Tromsø University 
Proteomics Platform (TUPP).  
TUPP prepared the protein gel-pieces for analysis. These protein gels were subjected in 
a gel reduction, alkylation and trypsin digestion (6 ng/μl trypsin (V511A, Promega, 
Wisconsin, USA). OMIX C18 tips (Varian, Inc., Palo Alto, CA, USA) were used for 
sample clean-up and concentration. 0.1% formic acid was added to the peptide mixture 
and loaded onto a Thermo Fisher Scientific EASY-nLC1000 system and EASY- Spray 
column (C18, 2 µm, 100 Å, 50 µm,50 cm). Next, peptides became fractionated through 
a 2-100% acetonitrile gradient in 0.1% formic acid over 50 minutes at a flow rate of 200 
nl/min (Shevchenko et al., 2007). Lastly, peptides become fragmented through a Q-
Exactive™ Hybrid Quadrupole-Orbitrap™ Mass Spectrometer (© 2015 Thermo Fisher 












Figure 2.2: Illustration of the Q-Exactive™ Hybrid Quadrupole-Orbitrap™ Mass Spectrometer 
(© 2015 Thermo Fisher Scientific Inc). The LC- eluate is loaded and travels through the capillary, S- lens, 
bent flatapole, the quadrupole further through the C-Trap, where the ions goes up to the orbitrap, where the ions 
are trapped and analyzed Each peptide fragment of interest is sent into the HCD, where they return to C-trap and 
ends up in orbitrap, where the peptides becomes fragmented and produces MS/MS spectrums (Michalski et al., 
2011).  
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2.2.15.1 Protein identification and processing of the peptide-fragment spectrums  
Data from the Q-Exactive™ Hybrid Quadrupole-Orbitrap™ Mass Spectrometer (Thermo 
Scientific™) was collected in data dependent mode using a Top10 method. Next, these data 
were processed through Proteome Discoverer™ software (Thermo Scientific™), which is a 
software used for identification of peptide spectrums obtained from MS. All fragmented 
peptide-spectrums were searched up against already known protein sequences from Homo 
Sapiens. This was done through the proteomic database, Uniprot (Consortium, 2015, UniProt, 
2016) using the Sequest HT program. The fragment mass tolerance was set to 0.02 Da and the 
peptide mass tolerance used in this search were 10ppm. First, peptides were filtrated and 
identified through a false discovery rate (FDR) set to 1%. Next, peptides bound to unspecific 
to GST proteins (negative control), where excluded. Lastly, keratin proteins were excluded. 




3.1 Establishing the GST-pulldown assay followed by MS, to identify putative 
protein interaction partners for the GOLD domain of FYCO1 
The idea was to perform an unbiased GST pulldown-MS study in order to identify putative 
interaction proteins for the GOLD domain of FYCO1. An overview of the study is illustrated 
in figure 3.1. As a starting point we had a plasmid ready for bacterial expression of the GOLD 
domain (amino acids 1333-1478 of FYCO1) fused to GST (we named this plasmid pDest15-
GOLD). This plasmid contains a T7 promoter (Figure 3.2). This T7 promoter makes the plasmid 
able to be transcribed by the viral RNA polymerase. Therefore GST-GOLD became expressed 
in E.coli strain containing a viral T7 RNA polymerase.  
The GST-GOLD was further purified from E.coli extract using glutathione-sepharose beads. 
GST-GOLD bound to beads was then incubated with mammalian cell extracts and GST 
pulldown experiments performed to isolate putative GOLD interaction proteins. HEK293 T-
REx Flp-In- and HeLa cells were used for this approach. The GOLD domain interacting 
proteins were separated by SDS-PAGE and identified by LC-MS/MS (Figure 3.1). The 
experiment was repeated eleven times and the results are therefore highly representative.  
Next, cDNA for Specific putative GOLD interaction proteins were ordered and cloned into 
different desired vectors. Interacting abilities were tested by in vitro and in vivo pulldowns and 
















Figure 3.1: An illustration of the work-flow over the different steps to LC-MS/MS.  
 
Figure 3.2: A plasmid map over pDest15`- GOLD. In this plasmid the GOLD domain of FYCO1 fused to 
GST is expressed from T7RNA polymerase promoter.   
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3.2 Identification of the GOLD domain interaction candidates 
The GST-tag on the GOLD domain was used for the purification, through its affinity for glutathione- 
sepharose beads. The GST-GOLD was produced and purified. GST-GOLD is located as a 40 kDa band, 
without any other unspecific bands. The same was true for GST (25 kDa) (Figure 3.3).  
 
 
Figure 3.3: Affinity purification of GST-GOLD with glutathione-Sepharose™ 4 Fast Flow beads 
(GE Healthcare). Glutathione S-transferase (GST) pull-down assay were used to purify the GST-GOLD domain 
(40 kDa) and GST (25 kDa). Protein samples before expression and protein after the purification were loaded on 
an SDS-PAGE. Unstained protein ladder (10-250 kDa) (Neb, # P7703S) was used as the Molecular Weight (MW) 
ladder. 
 
Next, a GST-pulldown experiments were performed where ~107 cells (HEK293 Flp-In T-REx 
and HeLa cells) were incubated with the GST or GST-GOLD protein-beads. Protein interaction 
candidates were co-precipitated together with GST-GOLD domain. These protein candidates 
were loaded onto LC-MS/MS and the protein identification was done using Proteome 
Discoverer™ 2.1 software (Thermo Scientific™). This software is a search engine, which uses 
the obtained mass spectrometry data to identify proteins from peptide sequence database 
(Perkins et al., 1999). In the current study UniProt (Consortium, 2015, UniProt, 2016) was used 











GST-GOLD  GST    
GST 
GOLD domain  
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The identified proteins from all the eleven experiments were run in parallel with GST, as a 
negative control, to exclude unspecific binding. All of the obtained protein candidates were 
filtered by specific criteria’s (Table 3.1). From these eleven experiments, all protein peptides 
were sorted into protein groups. In total, 182 proteins were identified (Appendix). How 
representative their co-precipitations were according to their obtained PSM value. #PSM is the 
match between our obtained spectrum and the highest-scoring peptide. In addition, 22% of the 
protein groups were only identified in HEK293 T-Rex Flp-In cells. However, 28% of the 
protein groups were only identified in HeLa cells. These results shown us that the protein 
distribution between these two cell lines were relative the same and the experiments were 
therefore merged. The cellular localization of each protein were obtained by the ProteinCenter 
software in the Proteome software Discovery program (Thermo Scientific™). The data shows 
that a highly number of the proteins were known to interact with membranes (22.8%) (Figure 
3.4). These proteins were of high interesting, due to FYCO1s membrane interacting function. 
In addition, some of these proteins were also found distributed in the nucleus, the cytoplasm, 
Golgi apparatus, mitochondrion and endoplasmic reticulum (ER) (Figure 3.4).  
 
Table 3.1: Protein filtration criteria’s in Proteome software Discovery (Thermo 
Scientific™). 
Criteria’s Description  
False discovery rate (FDR), below 1% The ratio between false PSM and the 
number of PSM obtained above the score 
threshold (1%).  
Not bound to GST-beads Proteins are not co-precipitated with GST-
beads 
Keratin excluded  Keratin is one of the most normal 






Figure 3.4: The known distribution (%) of protein interaction candidates in different cellular 
components. Distribution (%) of the protein-interaction candidates in different cellular compartments: 
membrane, nucleus, cytoplasm, cytosol, Golgi apparatus, mitochondrion, endoplasmic reticulum (ER) and in other 
components were calculated by the 182 proteins obtained from the ProteinCenter software from Proteome software 
Discovery (Thermo Scientific™).  
 
Next, a cut-off value for the 182 interaction candidates were set. All protein candidates should 
be co-precipitated in at least six of the eleven experiments. From the cut-off, 30 putative 
interacting proteins were selected from how many times they were co-precipitated together with 
the GOLD domain of total eleven experiments (Table 3.2). These were also sorted according 
to their peptide spectrum matches (#PSM), since #PSM is a relative indication of the number 
of identified peptide spectrum matches for each protein and describe the identification of the 


































Table 3.2: Putative interacting proteins (30) were separated according to the number of positive 
identifications throughout the eleven experiments.  




Tubulin, alpha-4A chain TUBA4A  11/11 338 
DnaJ homolog subfamily A member 1 DNAJA1  10/11 212 
ADP/ATP translocase 2 SLC25A5  10/11 199 
Thioredoxin domain-containing protein 5 TXNDC5  9/11 123 
DnaJ homolog subfamily A member 2 DNAJA2  9/11 116 
ATP synthase subunit alpha, mitochondrial ATP5A1  9/11 109 
Pyrroline-5-carboxylate reductase 2 PYCR2  9/11 97 
Carbamoyl-phosphate synthase, mitochondrial CPS1  9/11 71 
Guanine nucleotide-binding protein subunit beta-2-like 1 GNB2L1  9/11 58 
Protein NipSnap homolog 1 NIPSNAP1  8/11 73 
DnaJ homolog subfamily A member 3, mitochondrial DNAJA3  8/11 36 
D-3-phosphoglycerate dehydrogenase PHGDH  8/11 35 
DnaJ homolog subfamily B member 11 DNAJB11  8/11 31 
2’,3’-cyclic-nucleotide 3’-phosphodiesterase CNP  8/11 28 
ATP synthase subunit gamma, mitochondrial ATP5C1  8/11 26 
Cytochrome b-c1 complex subunit 2, mitochondrial UQCRC2  8/11 23 
60kDa heat shock protein, mitochondrial HSPD1  7/11 34 
Mitochondrial import inner membrane 50 TIMM50  7/11 27 
RuvB-like 2 RUVBL2  7/11 9 
Delta(24)-sterol reductase DHCR24  7/11 8 
Calcium-binding mitochondrial carrier protein Aralar 2 SLC25A6  6/11 169 
Cytochrome c1, heme protein, mitochondrial CYC1  6/11 34 
Heterogeneous nuclear ribonucleoprotein U HNRNPU  6/11 32 
ADP- ribosylation factor 4 ARF4  6/11 31 
Protein NipSnap homolog 2 GBAS  6/11 18 
Vacuolar protein sorting-associated protein 4A VPS4A  6/11 18 
Heterogeneous nuclear ribonucleoproteins A2/B1 HNRNPA2B1  6/11 14 
Lysophosphatidylcholine acyltransferase 1 LPCAT1  6/11 12 
DNA eplication licensing factor MCM7 MCM7  6/11 11 
Ras-related protein Rap-1b RAP1B  6/11 8 
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Figure 3.5: The 30 selected protein-interaction candidates arranged by their #PSM. These 
candidates are sorted by their #PSM value, from highest to lowest. A: Tubulin, alpha-4A chain (TUBA4A), DnaJ 
homolog subfamily A member 1 (DNAJA1, ADP/ATP translocase 2 (SLC25A5), Calcium-binding mitochondrial 
carrier protein Aralar2 (SLC25A6), Thioredoxin domain-containing protein 5 (TXNDC5), DnaJ homolog 
subfamily A member 2 (DNAJA2), ATP synthase subunit alpha, mitochondrial (ATP5A1), Pyrroline-5-
carboxylate reductase 2 (PYCR2), Protein NipSnap homolog 1 (NIPSNAP, carbamoyl-phosphate synthase, 
mitochondrial (CPS1), Guanine nucleotide-binding protein subunit beta-2-like 1 (GNB2L1), DnaJ homolog 
subfamily A member 3, mitochondrial (DNAJA3), D-3-phosphoglycerate dehydrogenase (PHGDH), 60kDa heat 
shock protein, mitochondrial (HSPD1), Cytochrome c1, heme protein, mitochondrial (CYT1), Heterogeneous 
nuclear ribonucleoprotein U (HNRNPU), DnaJ homolog subfamily B member 11 (DNAJB11) and ADP- 
ribosylation factor 4 (ARF4). B: 2’,3’-cyclic-nucleotide 3’-phosphodiesterase (CNP), Mitochondrial import inner 
membrane (TIMM50), ATP synthase subunit gamma, mitochondrial (ATP5C1), Cytochrome b-c1 complex 
subunit 2, mitochondrial (UQCRC2), Vacuolar protein sorting-associated protein 4A (VPS4A), Protein NipSnap 
homolog 2 (NipSnap2/GBAS), Heterogeneous nuclear ribonucleoproteins A2/B1(HNRNPA2B1), 
Lysophosphatidylcholine acyltransferase 1 (LPCAT1), DNA eplication licensing factor MCM7 (MCM7), RuvB-
like 2(RUVBL2), Delta(24)-sterol reductase (DHCR24) and Ras-related protein Rap-1b (RAP1B).  
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3.3 Comparison of this study with a previously reported IP-MS study with full-length 
FYCO1 
An unbiased interaction study of full-length FYCO1 has previously been published by Christian 
Behrends in 2010 (Behrends et al., 2010). In this study, proteins from HEK293 cell lysates were 
tested for their interacting capabilities for full-length FYCO1 by immune-precipitation and LC-
MS/MS identification. This study sought to create an organized network of the human 
autophagy system. A list of 333 putative interaction candidates for full-length FYCO1 were 
here identified (Behrends et al., 2010). The result from this study was compared with our 
results. Ten protein interaction candidates for the GOLD domain were overlapping with the 
protein candidates from the Behrends list (Figure 3.6). The proteins are arranged by their 
obtained #PSM from our study. Seven of the ten proteins showed a high PSM value. The 
remaining three have lower PSM values, but were ranged higher in Behrends list (Figure 3.6).   
 
 
Figure 3.6: Ten protein interaction candidates identified in experiments with 
immunoprecipitation of full-length FYCO1 and the GST pulldown with the isolated GOLD 
domain. These protein candidates were found in the co-precipitation with both full-length FYCO1 and for the 
GOLD domain. They are here arranged according to their #PSM obtained in our study. These putative proteins 
are: Tubulin, alpha-4A chain (TUBA4A), ADP/ATP translocase 3 (SLC25A6), ATP synthase subunit alpha, 
mitochondrial (ATP5A1), Heterogeneous nuclear ribonucleoprotein U (HNRNPU), Heterogeneous nuclear 
ribonucleoproteins A2/B1 (HNRNPA2B1), Vacuolar fusion protein CCZ1 homolog B (CCZ1B), RuvB-like 2 
(RUVBL2), nuclease-sensitive element-binding protein 1 (YBX1), Vacuolar fusion protein MON1 homolog B 


















3.4 Selection of nine potential GOLD domain interacting proteins for further studies 
From the 30 protein interaction candidates, nine proteins were selected for further studies 
(Table 3.3). These nine candidates were chosen according to the reported function and 
localization, but also based on other reasons related to activities within our research group and 
if cDNA were available or not. Further verification assays were used to look at their level of 
direct and indirect interactions to the GOLD domain.  
 
Tubulin, alpha-4A chain (TUBA4A) 
TUBA4A was pulled down in all eleven LC-MS/MS experiments and had the highest #PSM 
value (338) among the 30 selected candidates. For this reason, TUBA4A was chosen for further 
studies. However, Crapome (a database used to identify the distribution level of proteins form 
other proteomics experiments) identified TUBA4A as a protein frequently co-precipitated in 
different affinity interaction assays (e.g. immune precipitation with GST-, FLAG- epitope tags) 
(data not shown). It is showento be distributed in the cytoplasm, cytoskeleton, cytosol and 
extracellular environment (information obtained by ProteinCenter software (Thermo 
Scientific). MT are composed of α- and β- tubulin. Here TUBA4A is one of the isoforms of α-
tubulin. MT are involved in intracellular transport, cell motility, mitosis and maintain of cell 
polarity and shape (Conde and Caceres, 2009). FYCO1 is known to interact with MT through 
motor proteins (Raiborg et al., 2015, Pankiv et al., 2010). The GOLD domain can have an 
interaction towards TUBA4A. 
  
DnaJ homolog subfamily A member 1 (DNAJA1)  
DNAJA1 was pulled down in ten of eleven (91%) LC-MS/MS experiments. Its high #PSM 
value (212) makes it one of the best interaction candidates for the GOLD domain. In addition, 
DNAJA1 is not often co-precipitated in protein interaction studies (Crapome database) (data 
not shown). This increases its chance to be involved in the interaction with the GOLD domain. 
DNAJA1 is distributed in the cytoplasm, cytosol, ER, on membranes, mitochondrion and in the 
nucleus (information obtained by ProteinCenter software (Thermo Scientific). It is known to 
work as a co-chaperone of heat shock protein 70 (Qiu et al., 2006).   
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Thioredoxin domain-containing protein 5 (TXNDC5)  
TXNDC5 was pulled down in nine of eleven (82%) LC-MS/MS experiments. It makes a good 
putative interaction candidate by having one of the best identification rates and a high #PSM 
value (123). In addition, TXNDC5 is not often seen to co-precipitate in protein-interaction 
studies (Crapome database) (data not shown). TXNDC5 is present in ER and in the plasma 
membrane (information obtained by ProteinCenter software (Thermo Scientific) and is found 
to interact with the insulin-sensing receptor, AdiporR1. This suggest that TXNDC5 is involved 
in adiponectin receptor biology and signaling (Charlton et al., 2010).  
 
NipSnap homolog 1 (NIPNSNAP 1) and NipSnap homolog 2 (NIPSNAP2 /GBAS)  
NIPSNAP1 and GBAS are homologs of each other and share similarities in structure and 
function. NIPSNAP1 was pulled down in eight of eleven (73%) LC-MS/MS experiments and 
GBAS was pulled down in six of eleven (54%) LC-MS/MS experiments. The chance of 
interaction to the GOLD domain is higher for NIPSNAP1 than GBAS. This is due to a higher 
#PSM value for NIPSNAP1 (73) than GBAS (18). The protein function and localization is still 
debated, however it is thought to either be in the matrix or in the inner membrane of the 
mitochondrion. The possibility for interaction with the GOLD domain is reduced, if they are 
localized inside the mitochondria. Although, the proteins may interact with the full-length 
FYCO1 through its GOLD domain before or during their transport into the mitochondrion. 
NIPSNAP1 and GBAS has also been examined in our research group, and were therefore 
included in this study.  
 
RuvB-like 2 (RUVBL2)  
RUVBL2 was pulled down in seven of eleven (63%) LC-MS/MS experiments with a #PSM 
value of 9. It was included due to the interest of our research group. It is also interesting that it 
was found to co-precipitate together with TUBA4A (Biogrid3.4 (thebiogrid.org)) and that it 
came down together with mTOR by affinity capture-MS (Biogrid3.4 (thebiogrid.org)). It is an 
ATPase DNA helicase and involved as a regulator of ER stress-induced gene transcription 
(Marza et al., 2015). However, it is localized on membranes and in the cytoplasm (information 
obtained by ProteinCenter software (Thermo Scientific), which can make it available for 
FYCO1.  
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Vacuolar protein sorting-associated protein 4A (VPS4A)  
VPS4A was pulled down in six of eleven (54%) MS experiments with a #PSM value of 18. It 
was included due to the interest of our research group, and because of its function.VPS4A is 
known to interact with Ras-binding proteins and ESCRT-III complex (Zheng et al., 2012), and 
is involved in intracellular protein trafficking, as the transport of LE proteins (Scheuring et al., 
2001). These features gives VPS4A an interesting opportunity to interact with the full-length 
FYCO1, and from our results, through the GOLD domain. 
 
ADP- ribosylation factor 4 (ARF4)  
ARF4 was also included as one of the nine interaction candidates, being pulled down in six of 
eleven (54%) LC-MS/MS experiments and got a #PSM value of 30. Its identification rate and 
#PSM value makes it a likely interaction candidate. Since ARF4 already has been used in our 
laboratory, it could easily be tested against the GOLD domain. In addition, ARF4 is rarely 
identified in different affinity interaction assays (e.g. immune precipitation with GST-, FLAG- 
epitope tags) (Crapome database) (data not shown). ARF proteins belong to the Ras superfamily 
of small GTPases, which regulate vesicle traffic and organelle structures. Regulation of 
organelle structure has been shown to be done by recruiting  coat proteins, modulating structure 
of actin at the membrane surfaces and to regulate phospholipid metabolism (D'Souza-Schorey 
and Chavrier, 2006). ARF proteins may work together in the ER–Golgi system and at the 
plasma membrane (Donaldson and Jackson, 2011). These functions increase the chance for 
ARF proteins to interact with the FYCO1, and therefore the GOLD domain. 
 
Vacuolar fusion protein MON1 homolog B (MON1B)  
According to our result, by its low interaction rate (9%) and low #PSM value (4), MON1B is 
not one of the high interaction candidates for the GOLD domain. However, MON1B was 
included as a possible interaction candidate, due to its already known putative interaction 
against the full-length protein, FYCO1 (Behrends et al., 2010) and the interest of our research 
group. It is known that MON1B creates a complex with CCZ1. This complex functions as a 
GEF for Rab7. Rab7 becomes activated and associates strongly to PI3P positive membranes 
(Cabrera et al., 2014) and is shown to interact with the FYCO1 (Pankiv et al., 2010). MON1B 
is therefore a biased putative interaction candidate, which can have an interaction with full-
length FYCO1 through FYCO1s GOLD domain.  
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Table 3.3: Putative protein interaction candidates (9) for the GOLD domain 
selected for further study 







Tubulin alpha-4A chain TUBA4A 11/11 338 49.9 - Cytoplasm 
- Cytoskeleton 
- Cytosol 
DnaJ homolog subfamily A 
member 1 







containing protein 5 
TXNDC5 9/11 123 47.6 - ER 
- Organell 
lumen 
Protein NipSnap homolog 1 NIPSNAP1 8/11 73 33.3 - Membrane 
- Mitochondrion 
RuvB-like 2 RUVBL2 7/11 9 51 - Cytoplasm 
- Membrane 
- Nucleus 
Protein NipSnap homolog 2  GBAS 6/11 18 33.7 - Membrane 
- Mitochondrion 













MON1 homolog B MON1B 1/11 4 59 - Cytoplasm 
* Information obtained from ProteinCenter software from Proteome software 
Discovery 2.1 (Thermo Scientific™)  
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3.5 According to the in vitro pulldown assay, DNAJA1 may be the strongest direct 
interaction candidate for the GOLD domain  
Behrends and his co-workers showed earlier that TUBA4A, RUVBL2 and MON1B were 
observed to precipitate together with full-length FYCO1 (Behrends et al., 2010). Interestingly, 
these came also down in our interaction study, with the isolated GOLD domain of FYCO1. To 
examine their direct interaction abilities towards the GOLD domain, these proteins and the six 
other protein candidates were obtain through cDNA from our own plasmid archive (ARF4, 
GBAS, NIPSNAP1, MON1B and VPS4A) or ordered from the Harvard PlasmID collection 
(Harvard, 2016) (TUBA4A, DNAJA1, TXNDC5 and RUVBL2).The gateway pENTR cDNA 
plasmid constructs were obtained for five of the nine proteins chosen for further studies. These 
five, TUBA4A, DNAJA1, RUVBL2, ARF4 and TXNDC5 cDNAs were cloned into pDest-
Myc vector, which contains a T7 promoter and a myc-tag (Lamark et al., 2003).  GBAS, 
NIPSNAP1 and MON1B were already cloned into this pDest-Myc vectors. VPS4A was not 
available as a pENTR construct, Due to time limitations, VPS4A was not tested. However, the 
eight candidates were in vitro transcribed and translated in a reticulocyte lysate System 
(Promega) together with radioactive 35S- methionine. First, these in vitro transcribed proteins 
were incubated with empty glutathione-Sepharose beads, to exclude unspecific binding. Next, 
their protein interacting abilities for the GOLD domain were tested by a GST-pulldown assay. 
This was performed by incubating them together with GST-GOLD bound on glutathione-
Sepharose beads. In parallel, these protein candidates were incubated with GST-beads, to 
exclude their unspecific binding to GST (bound to glutathione-Sepharose beads). GST works 
here as a negative control. Their interactions were identified by measuring their radioactive 
methionine content. The binding intensity is due to the measured radioactive methionine, which 
is shown as dark bands on the autoradiography. The strength is dependent on the interaction-
strength towards the GST-GOLD domain. Unspecific interactions were excluded by the GST 
control.  
 
The data presented in figure 3.7 shows the in vitro binding between the bacterial expressed 
GST-GOLD domain and in vitro translated protein candidates. The bands on the 
autoradiography indicating 5% input indicate an efficient in vitro translation of most of the 
candidates, except for TXNDC5. TXNDC5 gave no in vitro translationand product. (Figure 
3.7C). Interaction against GBAS, MON1B and ARF4 were all tested three times. These data 
are therefore more significant than the other. NIPSNAP1, TUBA4A, DNAJA1 and RUVBL2 
were all tested once and additional experiments must be included to make any conclusion about 
their direct interaction to the GOLD domain.  
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Two strong bands were observed in most of the inputs. These two bands, are two different forms 
of the protein. The ribosome can bind to more than one start codon and make a truncated form 
of the protein, which makes these two bands. The largest band (upper) is the full-length form 
of the protein fused to myc-tag, whereas the smaller (lower band) is most likely a product 
without a myc-tag or a truncated form (Figure 3.7A). Therefore all bands found in the input 
were included in the interaction strength quantitation (Figure 3.8). Additional bands found only 
after the pulldown (not found in the input) as seen for DNAJA1, can be due to cleaved proteins 
(Figure 3.7C).  
 
Figure 3.8 shows the quantification of the interaction intensity towards the GOLD domain. In 
total, all interacting toward the GOLD domain were below 5 % (compared to the 5 % input). 
An interaction value below 5 % is define as a very weak interaction. However from our 
quantification results (Figure 3.8), regarding to the GST-control and comparing with the 5% 
input, DNAJA1 seems as the protein with the best interaction toward the GOLD domain. This 
was also observed in the autoradiograph (Figure 3.7C). GBAS is quantified as the second best 
interaction candidate. RUVBL2 and TUBA4A did not show any unspecific interaction against 
GST, which can make their observed weak binding specific (Figure 3.7C). While, NIPSNAP1, 
ARF4, MON1B were not observed to have a direct interaction against the GOLD domain.  
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Figure 3.7: In vitro interaction study of the protein-interaction candidates, MON1B, GBAS, 
NIPSNAP1, ARF4, TXNDC5, DNAJA1, TUBA4A and GBAS. Autoradiograph of the GST pulldown 
assay between the GOLD domain fused to GST and immobilized on glutathione-sepharose beads and myc-tagged 
-MON1B, -GBAS, -NIPSNAP1, -ARF4, -TXNDC5, -DNAJA1, -TUBA4A  and -RUVBL2 produced by in vitro 
translation in presence of 35S-methionine. The in vitro translated proteins were incubated together with GST 
immobilized on glutathione- sepharose beads to exclude unspecific binding. The interaction/binding between 
GST-GOLD and in vitro translated protein-candidates are in regarding to a 5 % input and are resolved by SDS-
PAGE, stained by coomassie blue and detected by autoradiography (Fuji BAS-5000). Unstained protein ladder 
(10-250 kDa) (Neb, # P7703S) was used as the Molecular Weight (MW) ladder A: Autoradiograph of GST-GOLD 
and in vitro translated MON1B, GBAS and NIPSNAP1. B: Autoradiograph of GST-GOLD and in vitro translated 
ARF4, MON1B and GBAS. C: Autoradiograph of GST-GOLD and in vitro translated TXNDC5, DNAJA1 and 
TUBA4A. D: Autoradiograph of GST-GOLD and in vitro translated RUVBL2.  









Figure 3.8: Quantitation of binding to GST-GOLD domain in in vitro GST-pulldown assay. The 
percentage (%) pulldown values (y-axis) are the mean values from each of the interaction bands from the in vitro 
translated proteins pulled down (x-axis). The quantifications are relative to the GST control and the results were 
developed by using Image Gauge software 4.0 (Fuji). 
 
 
3.6 TXNDC5 precipitates together with the GOLD domain in vivo 
Next, an indirect interaction study was done by an in vivo GFP-Trap assay with immune-
precipitation against the myc-tagged protein candidates (Figure 3.9). Due to time limitations, 
only five of the interaction candidates, cloned into a myc-vector, were tested. These five were, 
RUVBL2, TUBA4A, TXNDC5, DNAJA1 and MON1B. This experiment was only done once. 
Each of these interaction candidates were transiently co-transfected together with the GOLD 
domain fused to a green fluorescent protein (GFP) into HEK293 Flp-In ZnF-FYCO1 knockout 
for FYCO1 #12 (HEK293 Flp-In ZnF-FYCO1 #12) by METAFECTENE® PRO system (Figure 
3.9A) (Olsvik et al., 2015). In addition, HEK293 Flp-In ZnF-FYCO1 #12 cells, stably 
expressing GFP-FYCO1, were transiently transfected with the same five Myc-tagged protein 
candidates (Figure 3.9B). In regard to the unspecific binding, the results showed TXNDC5 as 
the only possibly candidate that showed an interaction with the GOLD domain (Figure 3.9A). 
However, as previously known, Behrends showed earlier that endogenous TUBA4A, RUVBL2 
and MON1B were observed to precipitate together with full-length FYCO1 (Behrends et al., 
2010). Through our previous in vitro pulldown experiments, none of these seems to have a 
strong direct interaction towards the GOLD domain. This is true for their interaction in the IP 
as well. In this in vivo pulldown experiment relative to the unspecific binding, none of these 
candidates were observed to precipitate together with the GOLD domain. However, MON1B 




Figure 3.9: Immune-precipitation of GFP-tagged GOLD domain and FYCO1 co-expressed with 
Myc- tagged -RUVBL2, -TUBA4A, TXNDC5, -DNAJA1 and –MON1B. Unstained protein ladder (10-
250 kDa) (Neb, # P7703S) was used as the Molecular Weight (MW) ladder. Signals were detected by Lumi-
ImagerF1™ (Boehringer Mannheim) A: HEK293 Flp-In ZnF-FYCO1 #12 lysates were pulled down with GFP-
GOLD (GFP-trap). Myc-tagged proteins were immuno-precipitated with Myc-antibodies (upper panel). GFP-
tagged GOLD domain (lower panel) was immune precipitated with GFP antibodies. B: HEK293 Flp-In ZnF-
FYCO1 #12 stably expressing GFP-FYCO1 lysates were pulled down with GFP-FYCO1 (GFP-trap). Myc-tagged 
proteins were immuno-precipitated with Myc-antibodies (upper panel). GFP-tagged FYCO1 domain was immune 
precipitated with GFP antibodies (lower panel).  
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3.7 Expression of the GOLD domain in cells reveals a diffuse localization pattern  
Next, the cDNA for the GOLD domain was gateway-cloned into a pDest-mCherry-C1 tagged 
vector. This vector express the GOLD domain as a fusion with the red fluorescent protein 
mCherry. The GOLD domain has previously been cloned into a pDestEGFP-C1 with a GFP-
tag, so this was not done in this study. To examine differences in the expression level between 
the empty mCherry- and GFP vectors, these were transiently transfected into HEK293 Flp-In 
ZnF-FYCO1 #12 cells and examined by confocal microscopy. These were compared with the 
transiently transfected mCherry-GOLD and GFP-GOLD constructs (Figure 3.10). All cell-
transfections were performed using TransIT®-LT1 reagent (Mirusbio) system. Cells were fixed 
with methanol (100%) for 24 hours after transfection. Live cell imaging was done the following 
day after the transfection. All images were taken using laser scanning confocal microscope 780 
(LSM780) (Zeiss).  
 
In figure 3.10 the expression of the wildtype GOLD domain was compared tp the expression 
of the empty pDestEGFP (EGFP/GFP) - and pDest-mCherry (mCherry)-vectors. GFP and 
mCherry alone are diffusely expressed throughout the cell, with no specific structures seen. 
However, the GOLD domain is also diffusely expressed over the whole cell, but with somewhat 
stronger perinuclear localization. The perinuclear localization is shown as a “line” around the 
nucleus. This may indicate ER structures, but have to stain for this structure. In addition we 
looked at the expression level and localization of full-length FYCO1 in HEK293 Flp-In ZnF-
FYCO1 #12 cells stably expressing GFP-FYCO1. FYCO1 makes clear rings, both perinuclear 
and in the peripheral part of the cell (Figure 3.10).    
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Figure 3.10: Examine the expression differences between the empty EGFP- and mCherry- tags 
and the EGFP-GOLD domain, mCherry-GOLD domain and full-length GFP-FYCO1. HEK293 
Flp-In ZnF-FYCO1 #12 cells were transiently transfected with EGFP- and mCherry-tags, EGFP-GOLD domain, 
mCherry-GOLD domain and full-length GFP-FYCO1.The empty GFP- and mCherry –tag are both totally 
diffused expressed (upper image). EGFP-GOLD and mCherry-GOLD shoes both diffuse expression throughout 
the cell. The arrows point out structures which may be ER structures, found around the nucleus (middle images). 
The GFP-FYCO1 was observed to make ring structures (marked as arrows), both perinuclear and in the 








3.8 Generally difficult to examine co-localization together with the GOLD domain, 
because of its diffuse localization.  
Confocal microscopy was used to check for co-localization of the GOLD domain and putative 
interaction partners in cells. To examine these protein interactions by confocal microscopy, all 
proteins were expressed in a fluorescent tag or a myc-tag capable for labeling with an antibody, 
which can be visualized by an antibody. In this study, three of the protein interaction candidates 
(TUBA4A, RUVBL2, TXNDC5) were first gateway-cloned into mCherry-C1 vectors. The 
other candidates were expressed with a myc-C1 tag (MON1B and DNAJA1) or a GFP-C1 tag 
(VPS4A). All the tags were expressed on the N-terminal part of the proteins. NIPSNAP1 and 
GBAS have their N-terminus end processed before it becomes inserted into the mitochondrial 
membrane. Therefore, they need to be cloned into a C-terminal mCherry-tag. NIPSNAP1 and 
GBAS were therefore not included due to time limitation. ARF4 is another protein that was 
depend on its N-terminal end. ARF4 normally become myriosylated on its N-terminus, which 
is important for its binding capabilities to membranes (Antonny et al., 1997). ARF4 was not 
cloned into a vector containing a C-terminal fluorescence tag. Therefore, NIPSNAP1, GBAS 
and ARF4 were not included in this assay.  
 
Next, protein interaction candidates were either transiently transfected alone or transiently co-
transfected together with the GOLD domain in HEK293 Flp-In ZnF-FYCO1 #12 cells 
(TUBA4A, TXNDC5, RUVBL2, VPS4A, MON1B and DNAJA1). In addition, some of the 
protein interaction candidates (TUBA4A, TXNDC5, RUVBL2 and MN1B) were co-
transfected into HEK293 Flp-In ZnF-FYCO1 #12 cells stably expressing GFP-FYCO1. All 
cells were kept in their full growth medium (Dulbecco′s Modified Eagle′s Medium (DMEM) 
(Sigma, D6046), 10% FBS (Merck), 100U/ml Penicillin and100g/ml Streptomycin), seeded out 
with a cell concentration of ~  7000 cells/ well. The transient transfection was done the 
following day. The expression of FYCO1 in HEK293 Flp-In ZnF-FYCO1 #12 cells stably 
expressing GFP-FYCO1 was induces by tetracycline. Fixed with methanol (100%) was done 
the day after transfection.  
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Several of the protein interactions were examine for their co-localization with the GOLD 
domain or with the full-length FYCO1 by confocal microscope. The results showed still a 
diffused cellular expression and localization of GFP- and mCherry- GOLD domain for most of 
the co-transfected experiments. These co-localizations were examined by a line-plot 
measurement (Zen Blue software, Zeiss). The local co-localization can be measured through 
this type of plot, where an arrow through a structure can measure the intensity of the color 
channels (EGFP (green lines) and mCherry (red lines) (see Table 2.6) and the graphs can be 
examined by comparing their intensity.  
 
TUBA4A redistributes the GOLD domain to the centrosomes 
TUBA4A was identified by MS as one of the highest ranked protein interaction candidates to 
the GOLD domain. In addition, it is shown to be a protein interaction candidate for the full-
length FYCO1 (Behrends et al., 2010). HEK293 Flp-In ZnF-FYCO1 #12 cells was transiently 
co-transfected with mCherry-TUBA4A and EGFP-GOLD domain (Figure 3.11). When 
expressed alone, TUBA4A was observed diffusely through the cell, with a large perinuclear 
puncta/aggregate perinuclear at the centrosome (Figure 3.11A and C). However, when 
expressed alone, the GOLD domain does not associate with centrosomes (Figure 3.11B). When 
the GOLD domain was co-expressed together with TUBA4A, TUBA4A redistributed the 
GOLD domain to the centrosome. They were observed to be localizes on centrosomes by 
staining for anti-γ –tubulin, which is a centrosome marker (Figure 3.11C). These co-
localizations were verified by a line-plot measurement (two lower images) (Figure 3.11C). This 
suggests an interaction between TUBA4A and the GOLD domain in cells. In addition, full-
length FYCO1 co-expressed with TUBA4A showed structures that could be observed to co-
localize with what likely are the centrosome. This must, however, be verified by centrosome 
staining. However, the localization and distribution of TUBA4A was observed to be changed 
after the co-expressing with full-length FYCO1. TUBA4A is shown to locate to similar rings 









































Figure 3.11: TUBA4A redistributes the GOLD domain to the centrosomes 
A: HEK293 ZnF-FYCO1 #12 cells were transiently transfected with mCherry-TUBA4A. Scale bare 20 µm 
B: HEK293 ZnF-FYCO1 #12 cells were transiently transfected with EGFP-GOLD and stained for anti- γ-
Tubulin. Scale bare 20 µm. C: HEK293 ZnF-FYCO1 #12 cells were transiently co-transfected with 
mCherry-TUBA4A and EGFP-GOLD. The cells were stained for anti- γ-Tubulin. Scale bare 5 µm. Co-
localization is measured by a line-plot (lower image), where the intensity of EGFP (green line), mCherry 
(red line) and anti-Tubulin (grey line) were compared. D: HEK293ZnF-FYCO1 #12 cells stably expressing 
GFP-FYCO1 were transiently transfected with mCherry-TUBA4A. Scale bare 20 µm. Co-localization is 
measured by a line-plot (lower image) where the intensity of EGFP-FYCO1 and mCherry-TUBA4a were 







TXNDC5 seems to be concentrated on ring structures formed by FYCO1  
HEK293 Flp-In ZnF-FYCO1 #12 cells were transiently transfected with mCherry-TXNDC5, 
EGFP-KDEL and EGFP-GOLD (Figure 3.12A-C). When expressed alone, TXNDC5 is 
diffusely expressed over the whole cell and EGFP-KDEL shows clear ER structure (Figure 
3.12A). KDEL is a C-terminal Lys-Asp-Glu-Leu ER retention signal sequence fused to GFP, 
and is used as an ER marker (Figure 3.12A) (Munro and Pelham, 1987). Human Protein Atlas 
(Uhlen et al., 2015) was used to identify the location of TXNDC5, TXNDC5 are known to be 
localized to ER structures (ProteinAtlas). The co-expression of TXNDC5 together with KDEL 
does not change the distribution of TXNDC5 or KDEL. ER structures can easily be damaged 
and the cell structures were examined in live cells. TXNDC5 is dynamic, but does not have the 
same dynamics as the KDEL structures (data not shown) (Figure 3.12B). TXNDC5 does not 
co-localize with KDEL. This was also observed by the line-plot (Figure 3.12B). In figure 3.12C 
the HEK293 Flp-In ZnF-FYCO1 #12 cells are fixed. The fixation influenced the KDEL 
structures, and it was not possible to see the KDEL expression. However, TXNDC5 is observed 
to be localized perinuclear as a line around nucleus. This is a similar localization as the GOLD 
domain (Figure 3.10). TXNDC5 is not as much localized in the nucleus as it was observed in 
the live cells. TXNDC5 share same cytosolic distribution as the GOLD domain (Figure 3.12C). 
Through the observation and the line-plot measurements, TXNDC5 is partial associated with 
the GOLD domain (Figure 3.12C). TXNDC5 was co-expressed in HEK293 Flp-In ZnF-FYCO1 
#12 cells stably expressing GFP-FYCO1 (Figure 3.12D).The result shows us that TXNDC5 is 
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Figure 3.12: TXNDC5 seems to be concentrated on ring structures formed by FYCO1  
A: HEK293 ZnF-FYCO1 #12 cells are transfected with mCherry-TXNDC5 (left) and with GFP-KDEL 
(right). These images are of live cells. Scale bar 20µm. B: HEK293 ZnF-FYCO1 #12 Co-transfection with 
mCherry-TXNDC5 and EGFP-KDEL. These images are of live cells. The co-localization in measured by a 
line-plot (lower image), where the intensity of EGFP (green line) and mCherry (red) were compared. Scale 
bare 20µm C: Co-transfection with mCherry-TXNDC5 and the EGFP-GOLD domain. These cells are fixed 
with methanol (100%). The co-localization in measured by a line-plot (lower image), where the intensity of 
EGFP (green line) and mCherry (red line) were compared. Scale bare 5µm. D: HEK293 Flp-In ZnF-FYCO1 
#12 cells stably expressing GFP-FYCO1 Transfected with mCherry- TXNDC5. The co-localization in 
measured by a line-plot (lower image), where the intensity of EGFP (green line) and mCherry (red line) were 
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RUVBL2 is diffuse, but has a similar perinuclear distribution as the GOLD domain  
HEK293 Flp-In ZnF-FYCO1 #12 cells were transiently transfected with RUVBL2 and the 
GOLD domain (Figure 3.13). When expressed alone, RUVBL2 is distributed mainly in the 
cytoplasm, but also observed in the nucleus (Figure 3.13A). When the GOLD domain was 
expressed together with RUVBL2, RUVBL2 seems to get a more early ER structure, and less 
localized in the nucleus (Figure 3.13B). RUVBL2 is diffuse, but has a perinuclear distribution 
similar to the GOLD domain. The line-plot shows a co-localization between RUVBL2 and the 
GOLD domain (lower image) (Figure 3.13B).  
This is due to the diffuse expression of both the GOLD domain and RUVBL2. In addition, 
RUVBL2 became transfected into HEK293 Flp-In ZnF-FYCO1 #12 cells stably expressing 
GFP-FYCO1. This result shows that RUVBL2 are distributes in the cytosol and makes clear 
rings where FYCO1 is observed. According to the line-plot, the association between RUVBL2 












 Figure 3.13: RUVBL2 shows expression similarities with the GOLD domain and locsted to ring 
structures made by full-length FYCO1. A: HEK293 Flp-In ZnF-FYCO1 #12 cells transfected with 
mCherry- RUVBL2. This image was taken of live cells. Scale bar 20µm. B:  HEK293 Flp-In ZnF-FYCO1 #12 
cells co-transfected with mCherry-RUVBL2 and the EGFP- GOLD domain. Cells were fixated with methanol 
(100%). Scale bar 20µm. The co-localization between RUVBL2 and the GOLD domain was measured by a line-
plot (lowest image), where the intensity between the EGFP (green line) and mCherry (red line) levels were 
compared. C: HEK293 Flp-In ZnF-FYCO1 #12 stably expressing GFP-FYCO1 co-transfected with RUVBL2. 
Cells were fixated with methanol (100%). Scale bar 20µm. 
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VPS4A affect the expression and localization of the GOLD domain  
Overexpressed VPS4A is known from earlier studies to make aggregated puncta’s (Bishop and 
Woodman, 2000). In our results, shown in figure 3.14, VPS4A puncta’s are localized 
perinuclear. These puncta’s became smaller when they are co-expressed together with the 
GOLD domain (Figure 3.14B). The localization of the GOLD domain seemed to be affected 
by VPS4. The GOLD domain was observed to obtain a more VPS4A-like expression 
distribution in the cell when it was co-expressed with VPS4A. The co-localization between 
these VPS4A puncta and the dense GOLD structures was measured by a line-plot (lower image) 
(Figure 3.14B). Our line-plot results showed that it is observed a co-localization between 
VPS4A and the GOLD domain, but the intensity does not rise in the larger perinuclear puncta. 
More experiments are needed to clarify the issue of co-localization between VPS4A and the 
isolated GOLD domain as well as FYCO1.  
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Figure 3.14: VPS4A seems to affect the expression and localization of the GOLD domain. A: 
HEK293 Flp-In ZnF-FYCO1 #12 cells transfected with EGFP-VPS4. Scale bare 20 µm. B: HEK293 Flp-In ZnF-
FYCO1 #12 cells co-transfected with EGFP-VPS4A and mCherry-GOLD. Scale bare 20 µm. The co-localization 
level was measured by a line-plot (Lower image), where the intensity of EGFP (green line) and mCherry (red line) 
are compared. All cells were fixed with methanol (100%). 
 
 
Diffuse expression of MON1B in cytoplasm showed a partly overlap with the GOLD 
domain.  
MON1B was diffusely expressed in the cytoplasm, and not highly expressed inside the nucleus. 
The expression level and localization of the GOLD domain does not seem to be affected by 
MON1B. Transfection efficiency for the myc-MON1B alone was weak and not possibly to be 
observed. MON1B does not change the expression level or localization of the GOLD domain, 
but it is uncertain if MON1B expression level is influenced by the GOLD domain, since 
MON1B expression is examined alone. By the observation from the images and the line-plot 
measurements, MON1B seems to overlap with the GOLD domain were they have a higher 
expression level (Figure 3.15).   







Next, the association of MON1B together with full-length FYCO1 was examined in HEK293 
Flp-In ZnF-FYCO1 #12 cells stably expressing GFP-FYCO1. Our results shows that MON1B 
localized not to the FYCO1 rings, as for some of the other protein candidates (e.g. TUBA4A, 
TXNDC5 and RUVBL2) (Figure 3.15). However, the line-plot shows that the expression level 
of full-length FYCO1 is much stronger than for MON1B (Figure 3.15).More experiments are 
needed to clarify the issue of co-localization between MON1B and the isolated GOLD domain 
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Figure 3.15: Diffuse expression of MON1B in cytoplasm showed a partly overlap with the GOLD 
domain in specific areas in the cell. HEK293 Flp-In ZnF-FYCO1 #12 cells and HEK293 Flp-In FYCO1 #12 
cells stably expressing GFP-FYCO1 were used. All cells were fixated with methanol (100%) and stained for anti-
Myc. A: HEK293 Flp-In ZnF-FYCO1 #12 cells were co-transfected with myc-MON1B and EGFP-GOLD domain. 
Scale bar 20 µm. B: MON1B seems to partly overlap with the GOLD domain, shown by an arrow. Scale bare 5 
µm. Any co-localization was measured by a line plot (lower image) at specific localization, where the intensity of 
EGFP (green line) and myc-tag (red line) were compared. C: Transfection of myc-MON1B in HEK293 Flp-In 
ZnF-FYCO1 #12 cells stably expressing GFP-FYCO1 were done. Any co-localization was measured by a line plot 
(lower image) at specific localization, where the intensity of EGFP (green line) and myc-tag (red line) were 
compared.  Scale bare 5 µm.   
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Low transfection efficiency made it difficult to look at the expression level of DNAJA1 
together with the GOLD domain. 
The transfection of DNAJA1 alone into HEK293 Flp-In ZnF-FYCO1 #12 cells was not possible 
to achieve, and the co-transfection together with the GOLD domain was weak (Figure 3.16). It 
was difficult to examine their co-localization. The result from a line-plot measurements, 
showed a much higher expression level of EGFP-GOLD than for myc-DNAJA1. Therefore, 
co-localization between myc-DNAJA1 and EGFP-GOLD domain was difficult to examine 




Figure 3.16: Low transfection efficiency made it difficult to look at the expression level of DNAJA1 
together with the GOLD domain. HEK293 Flp-In ZnF-FYCO1 #12 cells were co-transfected with myc-
DNAJA1 with EGFP- GOLD domain (upper image).  Any co-localization was measured by a line plot (lower 
image) at specific localization, where the intensity of EGFP (green line) and myc-tag (red line) were compared. 
Scale bar 20µm. All cells were fixated with methanol (100%) and stained for anti-Myc-DNAJA1. 
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3.9 The L1376P mutation affect the expression level of the GOLD domain  
Next, the cell expression differences of the wildtype GOLD- and the mutant GOLD (L1376P) 
domain was compared. The mutant form of the GOLD domain (L1376P) in the full-length 
FYCO1 did not show any differences in cellular localization (Chen et al., 2011). Therefore it 
was interesting to see if the mutation in the isolated GOLD domain changed the cellular 
localization. The wild type GOLD domain and the mutant GOLD domain (L1376P) were 
transiently transfected into HeLa cells, human B3 lens cells and HEK293 Flp-In ZnF-FYCO1 
#12 cells (Figure 3.17). The GOLD domain is diffusely expressed throughout the cell in all of 
the cells types examined in this study. However, the mutant GOLD domain (L1376P) has a 
dramatic aggregated expression appearance distrunctly different from the wild type. This is 
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Figure 3.17: Expression of 
wild type EGFP-GOLD and 
mutant EGFP-GOLD 
(L1376P)-domain. B3 cells 
transiently transfected with wild 
type EGFP-GOLD and mutant 
EGFP-GOLD (L1376P)-domain. 
These cells were fixated with 
methanol (100%). Scale bare 20 
µm. HeLa cells transfected with 
wild type EGFP-GOLD and 
EGFP-GOLD (L1376P)-domain. 
Live cell imagining was used for 
these cells. Scale bar 20µm. In the 
lowest line HEK Flp-In ZnF- 
FYCO1 #12 cells were transient 
transfected with GFP-GOLD and 
GFP –GOLD (L1376P).  
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2.3 FYCO1 surrounds micronuclei like structures in human B3 lens epithelial 
cells  
Human B3 lens cells were transiently transfected with GFP-FYCO1 and the nucleus was 
visualized with DRAQ5. This revealed an interesting feature about FYCO1. FYCO1 appears 
to take up micronuclei, DNA-like structures (Figure 3.18). These w observed in approximately 
one time in each cell. Interestingly, this phenomenon did not appear in other cell lines, such as 
HeLa and HEK293 Flp-In ZnF-FYCO1 #12 (not shown). Obviously, more work is needed to 




Figure 3.18: Part of the cellular DNA appears to be integrated into FYCO1 structures. Confocal 
images of B3 cells transfected with EGFP-FYCO1. The nucleus was visualized with DRAQ5. All cells were 




The initial aim for this study was to identify putative interaction partners for the GOLD domain 
and the RUN domain of FYCO1. Unfortunately, as a result of technical problems and time 
limitations, we early ended up to exclude the study of the RUN domain. Instead, the focus was 
on the identification of protein interaction partners for the GOLD domain. In general, GOLD 
domains are located in several other proteins with diverse function, as ER to Golgi transport 
and Golgi dynamics (Anantharaman and Aravind, 2002). For p24 family proteins, the GOLD 
domain is located at the luminal side of ER, and it was thought that the GOLD domain interacted 
with luminal cargoes. A recent study reveal that one specific cargo 
(glycosylphosphatidylinositol-anchored proteins (GPA-AP) interact with p24 proteins through 
their α-helical region instead of its GOLD domain, which was the first prediction (Theiler et 
al., 2014). However, the GOLD domain of FYCO1 is located at the C-terminus and it has been 
supposed that it may be involved in protein interactions. Still, it has not been examined whether 
the GOLD domain can interact with other proteins. However, Pankiv et at earlier suggested that 
the GOLD domain of FYCO1 could have intramolecular interaction possibilities, which could 
have an inhibitory effect on its interaction with lipids (Pankiv et al., 2010). In addition, in a 
recent study the GOLD domain of SEC14-like domain of supernatant protein factor (SPF) was 
thought to acts as a regulator, through its intramolecular interaction abilities, which would 
change its conformation. This occurs to favor ligand binding and release during different 
synthetic steps (Christen et al., 2015). This led our thought towards the GOLD domain as an 
intramolecular regulator of FYCO1, which may regulate the binding capabilities of FYCO1 to 
other proteins. However, the GOLD domain can still be involved in protein-protein interactions, 
and we have examined the presence of possible interaction candidates.    
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The results obtained from the mass spectrometry identified putative interaction proteins that 
were co-precipitated together with the GOLD domain. Our study revealed 182 proteins as direct 
or indirect protein interaction candidates for the GOLD domain. The results are highly 
representative, due to our eleven mass spectrometry experiments, wherein unspecific 
interactions of GST have been excluded. A stringent identification cut-off was set to 
identification in six or more experminets. Here, 30 putative proteins precipitated together with 
the GOLD domain in six or more experiments. Nine protein interaction candidates, TUBA4A, 
DNAJA1, TXNDC5, NIPSNAP1, RUVBL2, GBAS, ARF4, VPS4A and MON1B were 
selected for further study. From these nine six were identified to interact with membranes 
(DNAJA1, NIPSNAP1, RUVBL2, GBAS, ARF4 and VPS4A) (Table 3.3). These results were 
interesting, since FYCO1 is known to be a membrane-associated transport protein through 
different effector proteins (Pankiv et al., 2010). TUBA4A, RUVBL2 and MON1B were 
proteins which came down both in an of the interaction study of full-length FYCO1 (Behrends 
et al., 2010) and in our study of the GOLD domain. These proteins we considered to have the 
highest change of having a positive interaction capability to FYCO1 through the GOLD 
domain. MON1B was ranked as one of the best candidates. However, this was not observed in 
our results, MON1B came down in only one of the eleven experiments and its PSM value of 
nine, was the lowest one compared to the other nine selected candidates. However, in the 
Behrends interaction study, TUBA4A and RUVBL2 were ranked lower than MON1B 
(Behrends et al., 2010). From our study, TUBA4A was the candidate with the highest PSM 
value (338) and ranked as the best interaction candidate for GOLD.  
In this current study, some of the candidates were tested for direct- and indirect interactions 
through in vitro (NIPSNAP1, GBAS, ARF4, DNAJA1, TUBA4A, RUVBL2 and MON1B) and 
in vivo (RUVBL2, TUBA4A, TXNDC5, DNAJA1 and MON1B) interaction assay for their 
interaction towards the GOLD domain and full-length FYCO1. From our in vitro and in vivo 
pulldown results, all of the tested protein interaction candidates were shown to have a very 
weak interaction affinity towards the GOLD domain.  
Our MS results does not separate direct- and indirect protein interactions, proteins that co- 
precipitated with the GOLD domain can interact with the GOLD domain both directly and 
indirectly. This may be the explanation for the weak interaction through the in vitro and in vivo 
protein interaction assays. In addition, indirect interactions may sometimes be excluded through 
the transient co-overexpression of two proteins (exogenous). The protein interactions are often 
through protein complexes. In these types of binding assays, we examine the binding efficiency 
of the transiently co-overexpressed proteins (exogenous). This high amount of exogenous 
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protein would have a higher chance to interact and bind to each other than the endogenous 
proteins. The level of endogenous proteins would be much lower than the co-transfected 
proteins. Therefore, indirect interactions of the exogenous proteins, which are dependent on a 
third endogenous protein, may be excluded because of the low protein level of the third protein 
compared to the transiently co-transfected proteins. However, this is not a completely safe 
assumption and direct interactions can only be rigorously tested by using purified proteins. 
Further, some protein-protein interactions can be dependent on the proteins post-translational 
modifications (PTMs). The PTMs would affect the protein interacting network (Duan and 
Walther, 2015). PTMs would not be found in in vitro assays, and PTMs may not always be 
present on transient transfection proteins, due to available enzymes, which prossess the PTMs. 
Hence, it is possible that selected protein interaction candidates can interact with the GFP- 
GOLD domain in cells even if our interactions assays does not convincingly indicate a direct 
interaction.  
Next, we were interested in examining the expression and localization of the selected protein 
candidates in human cells together with the GOLD domain and the full-length FYCO1. To 
examine this, an in vivo assay was used to identify their possible co-localization by confocal 
microcopy. The transient co-transfection of the GOLD domain together with the candidates 
makes it possible to examine their co-localization. The transient co-transfection increases the 
expression level of the protein of interest, and it would be easier to identify co-localization for 
these compared to the endogenous cellular proteins. To examine the co-localization of specific 
structures or localization, a line-plot was used. In this line- plot, it could be easier to verify if it 
was any association or co-localization. This measurement was done by comparing the intensity 
of the different fluorescent channels (GFP, mCherry, Alexa Fluor® 647, Alexa Fluor® 488 
(green) and Alexa Fluor® 555 (red)). Unfortunately, the GOLD domain was highly diffusely 
localized in cells. However, its expression was stronger in a line around the cellular nucleus, 
which can indicate early ER structures (was not verified in this study). These ER structures can 
be identified by an ER marker or by treating the cells with Brefeldin A (BFA). BFA inhibits 
the secretion of proteins from ER to the Golgi apparatus through the prevention of the formation 
of COPI-mediated transport vesicles (Orcl et al., 1991). This drug can be used to identify any 
localization arrangement of the GOLD domain. A Golgi marker would also help to look at the 
localization pattern of the GOLD domain. However, none of these treatments were done to the 
GOLD domain in this study, but must be done for further study. In this study, the two protein 
interaction candidates, TUBA4A and VPS4A, changed the localization of the GOLD domain 
(Figure 11C and 14B).  
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TUBA4A came down in all of the eleven experiments, including full-length FYCO1. It was 
therefore supposed that TUBA4A may be a specific interactor of the GOLD domain of full-
length FYCO1. In the further studies, TUBA4A was observed to be located at the centrosomes. 
TUBA4A seems to affect the localization of the GOLD domain and it was observed a 
redistribution of the GOLD domain to the centrosomes (Figure 3.11C) in association with 
TUBA4A. TUBA4A may directly or indirectly associate with the GOLD domain through a 
protein complex.  
VPS4A localized diffusely and into some perinuclear puncta/aggregates (Figure 3.14A). These 
puncta could be part of endosomes. This can be confirmed by staining for endosome markers 
(not done in this study). Rab5 can be used as an early endosome marker. Rab5 is known to be 
involved in regulating the motility of early endosomes on microtubules (Nielsen et al., 1999). 
Rab7 can be used as a late endosome marker, since Rab7 is known to regulate late endosome 
trafficking (Vanlandingham and Ceresa, 2009) (not used in this study). However, VPS4A was 
observed to affect the localization of the GOLD domain. The diffuse expression of the GOLD 
domain was changed somewhat into diffuse pattern that also contained some VPS4A-positive 
puncta. This observation could be seen in the line-plot (Figure 3.14B).  
 
The expression or localization level of full-length FYCO1 is not affected by either of the 
protein candidates  
Due to time limitation, only TUBA4A, TXNDC5, RUVBL2 and MON1B were transiently 
transfected into HEK293 Flp-In ZnF-FYCO1 #12 cells (knockout for FYCO1) stably 
expressing GFP-FYCO1. However, through our study MON1B did not seem to make as clear 
FYCO1 rings (Figure 3.15C) as the other protein candidates. The other protein candidates, 
TUBA4A, TXNDC5 and RUVBL2 showed similar features as FYCO1 (Figure 3.11D, 3.12D 
and 3.13C). However, TXNDC5 is reported to mainly be located in ER structures 
(ProteinAtlas). The rings of full-length FYCO1 is known to be from the ER membrane (Raiborg 
et al., 2015). Our results did not show any ER localization for TXNDC5 by an ER marker, 
KDEL (Figure 11B). However, ER is distributed throughout the cell, seen as different structures 
and in our study. TXNDC5 seemed to be one associated best with FYCO1 structures through 
the line-plot (Figure 3.12D). For further experiments, another ER marker or inhibitors as BFA 
can be used to examine if TXNDC5 is localized on other part of the ER.  
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The L1376P mutation caused aggregation of the GOLD domain. 
Mutations in FYCO1, including the GOLD domain mutation L1376P, have earlier been 
identified to cause autosomal-recessive congenital cataract (Chen et al., 2011). Here, we found 
that the mutant variant of the GOLD domain (L1376P) changed the expression pattern of the 
GOLD domain. The mutant variant was more aggregated than the wild type (Figure 3.17). This 
can suggest a misfolding of the GOLD domain, which can influence the export ability of 
FYCO1 in the lens. Mutations in FYCO1 have earlier been identified to cause autosomal-
recessive congenital cataract (Chen et al., 2011). Our observed expression differences between 
wild type GOLD domain and mutant GOLD domain (L1376P) may be speculated to be 
associated with vision loss in patients with autosomal recessive congenital cataracts. By these 
obtained results and already known information about this mutation, the GOLD domain may 
be involved in the transparency of the lens. Maybe through a regulation of protein interactions.  
In further work, staining against structures, such as p62, ubiquitin and stress granules would be 
interesting to understand the localization of the wild type GOLD versus the mutant GOLD 
domain. 
 
FYCO1 surrounds micronuclei-like structures in human B3 lens epithelial cells 
Another interesting feature of FYCO1 was the observed micronucleus-like, DNA- containing 
structures inside FYCO1 rings (Figure 3.18). This phenomenon was observed in human B3 lens 
cells. However, this phenomena have been shown for the endosomal sorting complex required 
for transport -III (ESCRT-III) subunit CHMP4B (Sagona et al., 2014). CHMP4B seems to share 
some similar features with FYCO1, such as mutations found in patients with a form for cataract. 
The mutation of CHMP4B has been shown to inhibit the localization of CHMP4A to 
micronuclei (Sagona et al., 2014). For further study, it would be interesting to investigate if 
micronuclei can be found inside the rings of the FYCO1 L1376P mutant. This result may reveal 
new insight in what degradation cargoes FYCO1 is transporting. Since VPS4A is involved with 
ESCRT-III filament turnover (Raiborg and Stenmark, 2009) it must be studied if VPS4A, 
CHMP4B and FYCO1 act together somehow in these micronuclei-like structures.   
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4.1 Conclusion and further perspective 
Our results suggest that the GOLD domain can interact with other proteins, such as TUBA4A 
VPS4A and TXNDC5. TUBA4A and VPS4Awere observed in our study to affect the 
localization and expression level of the transiently transfected GOLD domain. It is still unclear 
if these interactions are direct or indirect. TUBA4A redistribute the GOLD domain to 
centrosomes, where they all are associated together. In addition, VPS4A redistribute the GOLD 
domain into VPS4A-containing structures. However, TXNDC5 immune-precipitated together 
with the GOLD domain in vivo, and MON1B immune-precipitated together with the full-length 
FYCO1, which Behrends et al. have shown earlier (Behrends et al., 2010). This suggest an 
interaction possibility towards the GOLD domain and full-length FYCO1 respectively. 
However, further studies with additional bindings assay have to be performed to firmly 
conclude about the GOLD domain interactions focused on here 
 
Next, we found the GOLD domain to be diffusely expressed throughout the cells. However, in 
our current study, the mutated GOLD domain (L1376P) formed multiple small aggregates. As 
previously shown by Chen and colleagues, mutations in FYCO1 have been shown to form 
truncated proteins and cause termination of the peptide chain before the GOLD domain. The 
mutation L1376P was identified to affect the transparency of the lens. It would be interesting 
to further examine the role of the GOLD domain mutation in full-length FYCO1 in vivo. Will 
we observe micronuclei inside FYCO1 rings in human B3 cells with the L1376P mutant? Is 
there any role for FYCO1 in DNA degradation during lens transparency?  
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6 Appendix:  
Table 6.1 LC-MS/MS data over the 182 Proteins co-precipitated with the GOLD domain 
from HEK293 T-Rex Flp-In (HEK293) and HeLa cells. GST is used as negative control 
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